<SEC-DOCUMENT>0001193125-17-310298.txt : 20171016
<SEC-HEADER>0001193125-17-310298.hdr.sgml : 20171016
<ACCEPTANCE-DATETIME>20171016060911
ACCESSION NUMBER:		0001193125-17-310298
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20171016
FILED AS OF DATE:		20171016
DATE AS OF CHANGE:		20171016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		171137536

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d443954d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 5, 20 George Street, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 16 October 2017 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g443954txpg3a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">483 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steven Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr James Garner</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16 October 2017</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF MEETING</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, 16 October 2017 &#150; Australian oncology-focused biotechnology company Novogen Limited (ASX: NRT; NASDAQ: NVGN) is pleased to provide its Notice of
Meeting in respect of its forthcoming Annual General Meeting.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More information can be
found on the Company&#146;s website <U>www.novogen.com</U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please navigate through to
the AGM page for more information.</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology
company, based in Sydney, Australia. Novogen has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR
pathway, which is being developed to treat glioblastoma multiforme. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017. A second clinical program, TRXE-002-01 (Cantrixil) commenced a phase I
clinical trial in ovarian cancer in December 2016. In addition, the company has several preclinical programs in active development, the largest of which is substantially funded by a CRC-P grant from the Australian Federal Government.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">For more information, please visit: <U>www.novogen.com</U></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g443954txpg3b.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g443954t1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16 October 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Fellow
Shareholder, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I am pleased to invite you to attend the 2017 Annual General Meeting of the shareholders of Novogen Limited, which is scheduled to be held
at 2pm (Sydney time) on 15 November 2017 at K&amp;L Gates: Level 31, 1 O&#146;Connell Street, Sydney NSW 2000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosed with this letter is the Notice of
Meeting, which details the items of business to be covered at the Meeting. Each of the Resolutions that will be presented to shareholders is explained in detail herein. However, I wanted to take the opportunity to also offer some general background
remarks, as this is a particularly important moment in the evolution of our Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be aware that Novogen has been through a period of
remarkable transformation over the past two years. Your Board took the view that the long-term success of the Company depended upon us building a diversified portfolio of high-quality, clinical-stage pharmaceutical assets, the scientific excellence
and commercial potential of which could be recognised by sector specialist investors and potential partners. Only by so doing could we reasonably hope to grow the long-term value of the business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To this end, we have recruited a highly-credible and internationally experienced new management team, led by our Chief Executive Officer, Dr James Garner. We
have defined a clear strategy for the Company, which involves identifying high-potential programs in pharmaceutical companies, where some of the work has already been done, some of the investment made, some of the risk removed, and some of the
potential demonstrated, but which are no longer consistent with the strategic priorities of the company that discovered them. We aim to adopt these undervalued programs and demonstrate their potential through highly-focused development work, so that
we can partner them with other companies for commercialisation. It is an innovative approach, and one which we firmly believe represents the best opportunity to deliver value for patients and shareholders. We have put this strategy into practice
through the in-licensing of GDC-0084, a promising new therapy for glioblastoma, the primary and most aggressive form of brain cancer, from Genentech, one of the world&#146;s most successful oncology drug developers. We are actively searching for and
reviewing other clinical phase compounds that will augment our portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our new approach is tantamount to a reinvention of the Company, and your Board
feels that it is time to recognise this by changing the name and capital structure. Accordingly, two of the Resolutions that we have asked you to consider will effect a rebranding of Novogen to <B>Kazia Therapeutics Limited</B>, and a consolidation
of our common stock at a 10:1 ratio. We recognise that such measures are sometimes considered cosmetic, but I want to assure you that in this case they are carefully considered, and integral components of a well-planned corporate transformation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has been many things to many people, and we remain proud of our historical achievements. However, to fully realise our future potential, we need
our stakeholders to be able to see us with fresh eyes, and to consider us without the encumbrance of the Company&#146;s numerous and varied past iterations. With the imminent return of GDC-0084 to the clinic, and the successful transition of
Cantrixil into human trials last year, Novogen has earned the right to redefine itself, and your Board seeks your support for the Company&#146;s revitalised sense of purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drug development is invariably a capital-intensive business, and any company that pursues new therapies for a disease as challenging as cancer is required to
boldly make significant investments in order to have any chance of success. Your Board fully recognises the obligation this imposes to take the utmost care in the use of shareholder funds, and we have not been afraid to terminate unpromising
programs and to realise significant cost savings by eliminating expenditure. Indeed, we have taken it upon ourselves in recent months to shrink the size of the Board, and to reduce the average fees paid to each Director. We are carefully considering
all available options so that the work of the Company may continue to be appropriately funded. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g443954t2.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has achieved much in this past year, and your Board shares the understandable frustration of
Shareholders that these achievements are yet to be fully recognised by the market. The package of Resolutions that are being put forward at the upcoming Annual General Meeting have been carefully designed to remedy this, and I commend them to you in
the strongest possible terms. My fellow Directors and I are committed to working tirelessly to advance Novogen&#146;s important work, and we ask for your support to complete the Company&#146;s transformation and to place it on a solid foundation for
success in the year ahead. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g443954t3.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iain Ross </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman of the
Board </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVOGEN LIMITED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABN 37 063 259 754 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE MATTERS RAISED IN THIS DOCUMENT WILL AFFECT YOUR SHAREHOLDING IN THE COMPANY. YOU ARE ADVISED TO READ THIS DOCUMENT IN ITS ENTIRETY
BEFORE THE ANNUAL GENERAL MEETING REFERRED TO BELOW IS CONVENED. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IF YOU ARE IN ANY DOUBT ABOUT THE ACTION YOU SHOULD TAKE IN
RESPONSE TO THIS DOCUMENT, PLEASE CONSULT YOUR STOCKBROKER, SOLICITOR, ACCOUNTANT OR OTHER PROFESSIONAL ADVISER. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g443954tx03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF ANNUAL GENERAL MEETING, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY STATEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY FORM
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THIS IS A NOTICE OF THE 2017 ANNUAL GENERAL MEETING OF THE COMPANY TO BE HELD AT<B> </B>2 PM ON WEDNESDAY 15&nbsp;NOVEMBER 2017 AT THE
OFFICES OF K&amp;L GATES AT LEVEL 31, 1 O&#146;CONNELL STREET, SYDNEY NSW 2000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A PROXY FORM FOR USE AT THIS MEETING IS INCLUDED WITH THIS
DOCUMENT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TO BE VALID, PROXY FORMS MUST BE COMPLETED AND RETURNED TO THE COMPANY&#146;S SHARE REGISTRY, COMPUTERSHARE, BY<B> NO LATER THAN
5 PM (NEW YORK TIME) ON 7</B><B></B><B>&nbsp;NOVEMBER 2017.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx443954_1">PART A: ABOUT THESE DOCUMENTS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx443954_2">PART B: LETTER FROM THE CHAIR</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx443954_3">PART C: NOTICE OF GENERAL MEETING</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx443954_4">PART D: EXPLANATORY STATEMENT</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx443954_5">PART E: GLOSSARY </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx443954_1"></A>PART A: ABOUT THESE DOCUMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders in Novogen Limited ABN 37 063 259 754 (<B>Company</B>) are requested to consider and vote upon each of the Resolutions set out in the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can vote by completing and returning the Proxy Form <B>DIRECTLY</B> to the Depository in the manner set out on the Proxy Form. The Company&#146;s
Depository must receive your duly completed Proxy Form by no later than 5.00 pm (New York time) on Tuesday 7&nbsp;November 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A glossary of
capitalised terms used throughout this Document (including the Proxy Form) is contained in <B>Part E</B>. Unless expressly provided otherwise in this Document, each capitalised term used in this Document has the meaning given in <B>Part E</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Please read the whole of this Document carefully before determining how you wish to vote and then cast your vote accordingly. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PLEASE NOTE THAT IF YOU DO NOT VOTE YOUR SHARES THEN YOUR VOTE LAPSES. THE DEPOSITORY HAS BEEN INSTRUCTED NOT TO DIRECT UNVOTED SHARES TO THE CHAIRMAN OF
THE MEETING. ONLY BY COMPLETING THE ATTACHED PROXY FORM WILL YOU HAVE YOUR SAY IN THE MATTER OF THE RESOLUTIONS PUT TO THE MEETING. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx443954_2"></A>PART B: LETTER FROM THE BOARD </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16&nbsp;October 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Fellow Shareholder </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are pleased to invite you to attend the 2017 Annual General Meeting of the Shareholders of Novogen Limited, which is scheduled to be held at Level&nbsp;31,
1 O&#146;Connell Street, Sydney NSW 2000 at 2pm (Sydney time). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosed with this letter is the Notice of Meeting, which details the items of business to
be dealt with at the Meeting. We hope you will consider the matters presented to you in this Notice and support us in our endeavours to continue to grow the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The full range of R&amp;D activities of the Company is presented on the Novogen website (<U>www.novogen.com</U>). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AGENDA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The resolutions on the agenda for this Meeting
are for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Adoption of Remuneration Report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Re-Election</FONT> of Bryce Carmine; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Changing the name of the Company to Kazia Therapeutics Limited; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The consolidation of the Company&#146;s Shares by replacing each 10 Shares with one new Share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">Approval of Employee Share Option Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">Approval of Increased Placement capacity under ASX Listing Rule 7.1A; and </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except in cases where it is obliged
to refrain from making a recommendation, the Board recommends that Shareholders vote <B>FOR</B> all resolutions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BACKGROUND </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resolution 1 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to attract and retain appropriate
management expertise, the Remuneration Committee of the Board carefully benchmarks executive compensation against other comparable companies. Executives are typically remunerated through a fixed cash component, a cash-based short-term incentive
component based on delivery of value-driving objectives during each year, and a long-term incentive program utilising share options to align interests with shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It should be noted that the Remuneration Report in this year&#146;s Annual Report is complicated to a certain extent by significant change in the Key
Management Personnel during the year, and therefore includes several positions that have become redundant and several overlapping positions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors fees have recently been revised and on
average reduced to preserve the Company&#146;s cash position. <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director fees for the year ending 30&nbsp;June 2018 are anticipated to amount to less than $300,000. In addition, each of the
Directors has purchased Shares on market during FY 2017, and this serves to further align themselves to the interests of Shareholders </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resolution 2
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bryce Carmine brings very valuable and deep expertise in the field of drug development, including portfolio management skills, to the Board, and is
extensively connected in the life sciences and investment communities. He had made a strong contribution to the Board since joining in 2015, not least through his Chairmanship of the Scientific Committee and Audit Committee.&nbsp;&nbsp;&nbsp;&nbsp;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resolution 3 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has maintained its current
name for over two decades, but the business has transformed radically in the last two years. Increasingly, the history of the name &#145;Novogen&#146; makes it more challenging for investors and other stakeholders to focus on the new direction of
the business. Accordingly, the Board proposes changing the name of the Company to Kazia Therapeutics Limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resolution 4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The large number of Shares on issue results in increased costs for the Company, and causes the Share price to be low relative to the market capitalisation. The
proposed consolidation will reduce the Company&#146;s administrative and share registry costs in relation to the Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resolution 5 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently has an Employee Share Option Plan (ESOP) in place, but is required to obtain reauthorisation for this every three years, and is
accordingly seeking approval from Shareholders at this Annual General Meeting. In common with other early-stage growth companies, Novogen uses equity-based remuneration as part of the compensation and incentivisation of staff, and would otherwise be
required to make greater recourse to the Company&#146;s cash reserves in order to appropriately compensate and incentivise its staff. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resolution 6
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rule 7.1 allows for listed companies to issue up to 15% of their issued share capital in new equity on a rolling twelve-month basis.
Companies outside the ASX300 may additionally seek annual authorisation from Shareholders to place up to an additional 10% of their issued share capital under Listing Rule 7.1A. Such approval may only be sought at a company&#146;s annual general
meeting. This is a valuable facility that allows companies to respond promptly to maximise opportunities that may be afforded by capital markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, Novogen seeks to renew its additional 10% capacity under Listing Rule 7.1A. Approval has previously been sought, and granted, in the 2016, 2015,
and 2014 Annual General Meetings. In the last two years, no new equity securities have been issued under this facility, but the Company nevertheless considers it highly desirable to maintain maximal flexibility to fund itself under the most optimal
terms available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VOTING </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You
are encouraged to vote by completing the attached proxy form. To be valid for the purposes of the Meeting, Proxy Forms must be completed and returned as instructed by no later than 5.00 pm (New York time) on Tuesday 7&nbsp;November 2017. Full
instructions for voting by proxy are detailed on the back of the Proxy Form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your vote is important and we encourage you to complete the Proxy Form
accompanying this Document and return it to the Depository in accordance with the directions provided. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iain Ross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bryce Carmine</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Coffey</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Garner</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx443954_3"></A>PART C: NOTICE OF GENERAL MEETING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Novogen Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABN 37
063 259 754 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1: Time and Place of Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTICE </B>is hereby given that the Annual General Meeting of Novogen Limited ABN&nbsp;37 063&nbsp;259&nbsp;754 (<B>Company</B>) will be held at the
following time and location, and at that Meeting the business specified in Section&nbsp;3 below will be conducted. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wednesday 15&nbsp;November 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Time:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.00 pm (Sydney time)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Location:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The offices of K&nbsp;&amp; L Gates, Level&nbsp;31, 1 O&#146;Connell Street, Sydney NSW 20000</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2: Business of the Meeting </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FINANCIAL STATEMENTS AND REPORTS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To receive and consider the financial statements of the Group for the
12 months ended 30&nbsp;June 2017 and the related reports of the Current Directors and the Auditor (as contained in the Annual Report). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During this item
of business, Shareholders will have the opportunity to ask questions about and comment on the Company&#146;s management, operations, financial position, business strategies and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders will also have the opportunity for direct questions to the Auditor, to the extent relevant to the conduct of the audit of the Company, the
preparation and contents of the Auditor&#146;s Report contained in the Annual Report, the accounting policies adopted by the Company in the preparation of its financial statements and the independence of the Auditor. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RESOLUTION 1 &#150; ADOPTION OF REMUNERATION REPORT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To consider and, if thought fit, to pass the
following resolution as <B>an Ordinary Resolution</B>: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Resolution 1 &#150; Adoption of Remuneration Report </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;That, the Remuneration Report for the year ended 30&nbsp;June 2017 as set out in the Company&#146;s Annual Report for the year ended
30&nbsp;June 2017 be adopted.&#148; </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>*Please note that section 250R(3) of the Corporations Act 2001 (Cth) provides that the vote on
this resolution is advisory only and does not bind the Directors or the Company </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>C)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RESOLUTION 2 &#150; <FONT STYLE="white-space:nowrap">RE-ELECTION</FONT> OF BRYCE CARMINE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To consider
and, if thought fit, to pass the following resolution as <B>an Ordinary Resolution</B>: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Resolution 2 &#150; <FONT
STYLE="white-space:nowrap">Re-Election</FONT> of Bryce Carmine </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;To <FONT STYLE="white-space:nowrap">re-elect</FONT> Bryce
Carmine who retires by rotation in accordance with ASX Listing Rule 14.4 and clauses 21.1 and 21.7 of the Company&#146;s Constitution and being eligible, offers himself for <FONT STYLE="white-space:nowrap">re-election</FONT> as a Director.&#148;
</I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>D)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RESOLUTION 3 &#150; ADOPTION OF NEW NAME </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To consider and, if thought fit, to pass the following
resolution as <B>a Special Resolution</B>: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Resolution 3 &#150; Adoption of New Name </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;That, for the purpose of section 157(1) of the Corporations Act 2001, and for all other purposes, the Company&#146;s name be changed
from Novogen Limited to </I><B><I>Kazia Therapeutics Limited</I></B><I> with effect from the day on which the Australian Securities and Investments Commission alters the details of the Company&#146;s registration.&#148; </I></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>E)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RESOLUTION 4 &#150; CONSOLIDATION OF THE COMPANY&#146;S SHARES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To consider and, if thought fit, to pass
the following resolution as <B>a Special Resolution</B>: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Resolution 4 &#150; Consolidation of the Company&#146;s Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;That pursuant to Section&nbsp;254H(1) of the Corporations Act, and for all other purposes, the Shareholders approve the consolidation
of all of the Shares in the capital of the Company on the basis that every existing 10 fully paid ordinary share convert into one (1)&nbsp;fully paid ordinary share (rounded to the next whole number of shares), effective from the passing of this
resolution.&#148; </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>F)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RESOLUTION 5 &#150; APPROVAL OF EMPLOYEE SHARE OPTION PLAN </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To consider and, if thought fit, to pass the
following resolution as <B>an Ordinary Resolution</B>: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Resolution 5 &#150; Approval of Employee Share Option Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;That the shareholders <FONT STYLE="white-space:nowrap">re-approve</FONT> the Company&#146;s Employee Share Option Plan first adopted
by the Board of Directors on 4&nbsp;March 2015 for the purposes of ASX Listing Rules 7.1 and 7.2 Exception 9, section 200B of the Corporations Act 2001 (Cth) and for all other purposes, as laid before the meeting, a copy of which is available for
inspection at the registered office of the Company.&#148; </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>G)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RESOLUTION 6 &#150; APPROVAL OF ADDITIONAL PLACEMENT CAPACITY </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To consider and, if thought fit, to pass
the following resolution as <B>a Special Resolution</B>: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Resolution 6 &#150; Approval of additional placement capacity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;That pursuant to and in accordance with ASX Listing Rule 7.1A and for all other purposes, Shareholders approve the increase in the
capacity of the Company to issue equity securities up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions stated in the
Explanatory Memorandum which accompanies this Notice of Meeting.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OTHER BUSINESS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To transact any other business as may be brought before the Meeting in accordance with the Constitution of the Company and of which the requisite notice has
been given. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3: Directions Regarding Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Please read this Document carefully and in its entirety before determining how you wish to vote in relation to the Resolution, and then cast your vote
accordingly, either in person or by proxy or authorised representative. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>If you do not understand any part of this Document, or are in any doubt as
to the course of action you should follow in response to this Document, you should contact your stockbroker or financial or other professional adviser immediately. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Determination of Membership and Voting Entitlement for the Purpose of the Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of determining a person&#146;s entitlement to vote at the Meeting and in accordance with regulation 7.11.37 of the <I>Corporations
Regulations</I> <I>2001</I> (Cth), a person will be recognised as a Shareholder if that person is registered as a Shareholder at 7.00 pm (Sydney time) on Monday 13&nbsp;November 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How to Vote </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may vote by attending the Meeting in
person, by proxy or authorised representative. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting in Person </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To vote in person, please attend the Meeting on the date, time and place set out above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting by Proxy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To vote by proxy, please complete and
sign the Proxy Form enclosed with this Document as soon as possible and deliver the duly completed Proxy Form to the Share Registry in accordance with the instructions at the end of this document. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proxies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Shareholder entitled to attend and vote at the
Meeting pursuant to the Constitution is entitled to appoint no more than two proxies. Where more than one proxy is appointed, each proxy may be appointed to represent a specific proportion of the member&#146;s voting rights. A proxy need not be a
Shareholder. Any instrument of proxy deposited or received by the Company in which the name of the appointee is not filled in shall be deemed to be given in the favour of the Chair. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The instrument appointing a proxy, as well as any power of attorney (or a certified copy thereof) under which a
proxy is appointed, must be received by the Company or the Share Registry by no later than 2.00 pm (Sydney time) on Monday 13&nbsp;November 2017, in accordance with the instructions provided on the back of the Proxy Form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The instrument of appointment of a proxy must be executed by the appointor or its duly authorised representative. The Proxy Form which accompanies this Notice
may be used to appoint a proxy for the purposes of the Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Representative </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Shareholder that is a company and that wishes to appoint a person to act as its representative at the Meeting must provide that person with a letter executed
in accordance with the company&#146;s constitution and the Corporations Act authorising him or her to act as the Shareholder&#146;s representative. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Exclusion Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Resolution 1 </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of the following persons: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">a member of the Key Management Personnel; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">a closely related party of a member of the Key Management Personnel. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, a person described above may
cast a vote on this Resolution if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the person does so as a proxy that specifies how the proxy is to vote on the resolution; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the person is the Chair and has been appointed as a proxy (expressly or by default) without being directed how to vote on the Resolution; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in either case, the vote is not cast on behalf of a person described in paragraph (i)&nbsp;or (ii) above. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Resolution 5 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Listing Rule 7.2 Exception 9,
the Company will disregard any votes cast on Resolution 5 by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">the Directors of the Company (except one who is ineligible to participate in any employee incentive scheme); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">an associate of that person (or those persons). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the Company need not disregard a vote if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it is cast by a person as a proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Resolution 6 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will disregard any votes cast
on the proposed Resolution 6 by any person who may participate in the proposed issue and a person who might obtain a benefit, except a benefit solely in the capacity of a holder of ordinary securities, if the resolution is passed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the Company need not disregard a vote if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it is cast by a person as a proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OTHER BUSINESS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To transact any other business as may be
brought before the Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>By order of the Board </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: 16&nbsp;October 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx443954_4"></A>PART D: EXPLANATORY STATEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Explanatory Statement is included in and forms part of the Notice of Meeting. It contains an explanation of, and information about, the Resolutions to be
considered at the Meeting. It is given to Shareholders to help them determine how to vote on the Resolutions set out in the Notice of Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders should read this Explanatory Statement in full as the individual sections of this Document may not necessarily give a comprehensive review of the
Resolutions proposed in the Notice of Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are in doubt about what to do in relation to a Resolution, you should consult your stockbroker or
financial advisor or other professional advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Accounts and Reports </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Corporations Act requires the Company to lay before the Annual General Meeting the Financial Report, Directors&#146; Report (including the Remuneration
Report) and the Auditor&#146;s Report for the financial year ended 30&nbsp;June 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders will be offered the opportunity to discuss the
Financial Report, Directors&#146; Report and Auditor&#146;s Report at the meeting. Copies of these reports can be found on the Company&#146;s website http://www.novogen.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no requirement for Shareholders to approve the Financial Report, Directors&#146; Report and Auditor&#146;s Report. Shareholders will be offered the
following opportunities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">discuss the Annual Report for the financial year ended 30&nbsp;June 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">ask questions or make comments on the management of the Company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">ask the auditor questions about the conduct of the audit and preparation and content of the Auditor&#146;s Report. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to taking questions at the Annual General Meeting, written questions to the Chairman about the management of the Company, or to the Company&#146;s
auditor about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">the preparation and content of the Auditor&#146;s Report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">the conduct of the audit; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">accounting policies adopted by the Company in relation to the preparation of the financial statements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">the independence of the auditor in relation to the conduct of the audit, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">may be submitted no later than 5
business days before the Annual General Meeting to the Company Secretary at the Company&#146;s registered office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RESOLUTIONS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>Resolution 1 &#150; Remuneration Report</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board comment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board offers the following observations on the Remuneration Report: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Board and its Remuneration and Nomination Committee take a balanced view between the need to pay market rates to attract talent, and the financial resources of the Company. In particular, during the year ended
30&nbsp;June 2017, the Board and the Committee have focussed on hiring Senior Executives with appropriate global experience in the pharmaceutical industry so that the entity is best placed to deliver on the revised strategy. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Board notes that there was a level of overlap of Key Management Personnel (<B>KMP</B>) during the 2017 financial year, with certain executives leaving the Company and other new executives joining the team. Such
overlap is not anticipated to exist in future years. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors fees have recently been revised and on average reduced to assist the Company&#146;s cash position.
<FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors fees for the year ending 30&nbsp;June 2018 are anticipated to amount to less than $300,000. In addition, each of the Directors have purchased shares on market during FY 2017, and this
serves to further align themselves to the interests of shareholders </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As set out in the Notice of Meeting, any member of the KMP whose
remuneration details are included in the Remuneration Report, together with a closely related party of those members, are excluded from casting a vote on Resolution 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, the Board abstains from making a recommendation in relation to Resolution 1. The Chairman intends to exercise all undirected proxies in favour of
Resolution 1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background to the Resolution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Remuneration Report is contained in the &#147;Directors&#146; Report&#148; section of the Annual Report. Publicly listed companies are required to submit
their remuneration reports to a vote for adoption at each of their annual general meetings. Whilst the following resolution is to be determined as an ordinary resolution, it is advisory only and does not bind the Directors or the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Corporations Act provides that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">members of the Key Management Personnel whose remuneration details are included in the Remuneration Report (and any closely related party of those members) are not permitted to vote on a resolution to approve the
Remuneration Report, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">if the vote to approve the Remuneration Report receives a &#147;no&#148; vote by at least 25% of the votes cast, this will constitute a &#147;first strike&#148;. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As no &#147;first strike&#148; occurred at the Company&#146;s 2016 Annual General Meeting for the 2016 Remuneration Report, the current &#147;strike&#148;
count is zero. If a &#147;first strike&#148; was to occur at the 2017 Annual General Meeting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s subsequent Remuneration Report (in other words, the Company&#146;s Remuneration Report to be included in the 2018 Annual Report) must include an explanation of the Board&#146;s proposed action in
response to the &#147;no vote&#148; or an explanation of why no action has been taken; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">if the Company&#146;s subsequent (i.e. 2018) Remuneration Report also receives a &#147;no vote&#148; at the 2018 Annual General Meeting of at least 25% of the votes cast, then Shareholders at the 2018 Annual General
Meeting will be asked (at that 2018 Annual General Meeting) to vote on whether or not the Company is to hold another general Shareholder&#146;s meeting (within the following 90 days) to vote on a &#147;spill resolution&#148; under section 250V of
the Corporations Act. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During this item of business, Shareholders will have the opportunity to ask questions about and comment on the
Remuneration Report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Exclusion Statement: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The voting exclusion statement in respect of Resolution 1 is set out in Part C, Section&nbsp;2 of this Document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Resolution 2 &#150; <FONT STYLE="white-space:nowrap">Re-Election</FONT> of Bryce Carmine </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board
Recommendation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bryce Carmine brings very valuable and deep expertise in the field of drug development, including portfolio management skills, to
the Board, and for that reason the Directors (in the absence of Mr Carmine) unanimously recommend shareholders vote in favour of Resolution 2. The Chairman intends to exercise all undirected proxies in favour of Resolution 2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background to the Resolution </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clauses 21.1 of the
Company&#146;s Constitution of the Company&#146;s Constitution provides that, amongst other things, a Director must not hold office without <FONT STYLE="white-space:nowrap">re-election</FONT> for more than 3 years or following the third annual
general meeting after that Director last appointment or <FONT STYLE="white-space:nowrap">re-election,</FONT> whichever is the longer. Clause 21.7 provides that a Director who retires from office under the Constitution will be eligible for <FONT
STYLE="white-space:nowrap">re-election</FONT> to the Board at the meeting at which that Director retires from office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The length of time a Director has
been in office is computed from that Director&#146;s last election. Mr Carmine was last <FONT STYLE="white-space:nowrap">re-elected</FONT> to the Board at the 2015 Annual General Meeting of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at the date of this Notice of Meeting, the Board of the Company comprised of three Directors who are subject to rotation. The Director longest in office
without being <FONT STYLE="white-space:nowrap">re-elected</FONT> is Bryce Carmine and is therefore required to retire. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bryce Carmine credentials
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bryce Carmine spent 36 years working for Eli Lilly&nbsp;&amp; Co. and retired as Executive Vice President for Eli Lilly&nbsp;&amp; Co, and
President, Lilly <FONT STYLE="white-space:nowrap">Bio-Medicines.</FONT> Prior to this he led the Global Pharmaceutical Sales and Marketing and was a member of the company&#146;s executive committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bryce previously held a series of product development portfolio leadership roles culminating when he was named President, Global Pharmaceutical Product
Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Eli Lilly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During his career with Lilly
Bryce held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ&nbsp;&amp; General Manager of a JV for Lilly in Seoul, Korea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bryce has been CEO and Chairman of HaemaLogiX Pty Ltd, a Sydney based biotech company, since March 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bryce Carmine, being eligible, offers himself for <FONT STYLE="white-space:nowrap">re-election.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Resolution 3 &#150; Adoption of new name </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Recommendation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has been many things to many people, and we remain proud of our historical achievements. However, to fully realise our future potential, we need our
stakeholders to be able to see us with fresh eyes, and to consider us without any negative effects from the past. With the imminent return of <FONT STYLE="white-space:nowrap">GDC-0084</FONT> to the clinic, and the successful transition of Cantrixil
into human trials last year, your Board seeks your support for the Company&#146;s revitalised sense of purpose that it believes this will be assisted by the proposed change of its company name. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Directors believe that Resolution 3 is in the best interests of the Company and unanimously recommend that Shareholders vote in favour of this Resolution
3. The Chairman intends to exercise all undirected proxies in favour of Resolution 3. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background to the Resolution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with section 157 of the Corporations Act, if a company wants to change its name, it must pass a special resolution adopting a new name. It is
proposed that shareholders approve the Company&#146;s name being changed from &#145;Novogen Limited&#146; to &#145;Kazia Therapeutics Limited. The Board has approved this change of name subject to the approval of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASIC alters the details of the Company&#146;s registration. The name &#145;Kazia Therapeutics&#146; Limited has been reserved by the Company, applicable
trademarks have been applied for and domain names have been registered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Resolution 4 &#150; Share Consolidation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Recommendation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Consolidation is to implement a more appropriate capital structure for the Company going forward and to enable the Company to operate more
efficiently and reduce administrative costs associated with operating a share register with such a large number of shares on issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Directors believe
that Resolution 4 is in the best interests of the Company and unanimously recommend that Shareholders vote in favour of this Resolution 4. The Chairman intends to exercise all undirected proxies in favour of Resolution 4. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background to the Resolution </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Resolution 4 seeks
Shareholder Approval to consolidate the number of Shares on issue on a 1 new Share for every 10 existing Shares held as at 31&nbsp;December 2017 (<B>Consolidation</B>). Fractional entitlements arising from the consolidation will be rounded up to the
nearest whole number of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should this Resolution be approved, the following changes will be made to the Company&#146;s other equity securities:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Convertible notes: the number of ordinary shares to be issued will be adjusted to be one tenth of the number prior to the share consolidation. Accordingly, a remaining 2,400,000 shares stand to be issued to the
Convertible Noteholders upon achievement of the trigger event. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Options: the number of options will be consolidated in the same ratio as the ordinary capital, and the exercise price will be amended in inverse proportion to that ratio. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Timetable for Consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is an
indicative timetable for effecting the Consolidation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Event*</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Company advises ASX that Shareholders have approved the Consolidation in this resolution.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">15&nbsp;November&nbsp;2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Trading in the Consolidated securities on a deferred basis commences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">17&nbsp;November 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Issue Date. Deferred settlement market ends. Last Day for the Company to send notice to each securityholder advising of the number of securities held before and following the Consolidation.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">27&nbsp;November 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Normal (T+2) trading in Consolidated securities commences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">28&nbsp;November 2017</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Subject to the Listing Rules, dates subject to extension at the discretion of the Company. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional
Board Comments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A proportion of the Company&#146;s shares are held on NASDAQ in the form of American Depository Receipts (<B>ADR</B>s), which
currently consolidate ASX shares (with a corresponding change to the Company&#146;s option terms) at a 100:1 ratio. Should this Resolution 4 be approved by Shareholders, it is Novogen&#146;s intent to instruct the Depository Holder to adjust the
ratio at which the Company&#146;s ADRs consolidate in the same proportion as contemplated by this Resolution 4, namely from 100:1 to 10:1, so that the price of the NASDAQ securities is held is not anticipated to changes proportionally. This step (to
alter the number of Shares each ADR represents) does not require the approval of Shareholders, but is included here for information purposes so that Shareholders may consider the proposed Resolution 4 in its full context. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Resolution 5 &#150; Approval of Employee Share Option Plan </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Comments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Having recruited new leadership over the last two years the Board is committed to incentivising and retaining the Company&#146;s personnel in a manner which
promotes alignment of their interests with shareholder interests, whilst ensuring our remuneration package for all eligible participants is market-competitive. The company&#146;s ability to execute our strategy is dependent on the experienced talent
we have recruited, and their retention and alignment with shareholders&#146; interests is critical. At the same time, the Company desires to maintain flexibility to respond promptly to maximise opportunities afforded by capital markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, the Board seeks further shareholder approval of the Company&#146;s <U>existing</U> employee share option plan (<B>ESOP</B> or <B>Plan</B>) for
the purposes of ASX Listing Rule 7.2 Exception 9. A summary of the ESOP is set out later in these Explanatory Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Directors are excluded from
voting upon this resolution pursuant to the ASX Listing Rules, the Directors will not make a recommendation to shareholders with respect to vote in relation to this Resolution. The Chairman intends to exercise all undirected proxies in favour of
Resolution 5. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background to the Resolution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where Resolution 4 in this Notice of Meeting (<B>Consolidation</B>) is approved, any Options (and Shares upon exercise of any Options) issued under the Plan
after the implementation of the Consolidation will be issued on the basis that the exercise price and number of Shares to issue on an exercise of an Option will be calculated and stated in the terms of the Options on a post Consolidation basis. Any
Options issued under the Plan prior to the implementation of the Consolidation will be adjusted in accordance with the ASX Listing Rules (by a proportionate increase in the exercise price and a decrease, in the corresponding proportion, in the
number of Shares to issue upon an exercise of the Option) such that the Option holder will be in no worse position as a result of the Consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporations Act </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Section</I><I></I><I>&nbsp;200B of the Corporations Act</I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;200B of the Corporations Act
prohibits a company from providing a benefit in connection with the retirement of a managerial or executive officer (<B>Employment Retirement Benefit</B>) unless there is prior shareholder approval under section 200E. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholder approval in accordance with sections 200B and 200E of the Corporations Act is sought under Resolution 5 in connection with the provision of
options under the terms of the proposed Employee Share Option Plan, as in certain circumstances the Board has the power to accelerate vesting of option issued under the Employee Share Option Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For instance, where shareholders pass Resolution 5, the Board may accelerate vesting of option entitlements on a retirement of a managerial or executive
officer - which could constitute a benefit otherwise prohibited under section 200B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has not determined that it will exercise discretion to
grant any Employment Retirement Benefits. In the circumstances of a possible Employment Retirement Benefit, the value of the benefits that the Board may give under the Plan cannot be determined in advance, as many of the factors that will or are
likely to affect that value will not be known until the time the benefit is decided to be awarded (if at all). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specifically, the value of an Employment
Retirement Benefits will depend on a number of factors, including the Company&#146;s share price at the time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ASX Listing Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Listing Rule 7.1 requires shareholder approval for an issue of equity securities if, over a rolling <FONT STYLE="white-space:nowrap">12-month</FONT> period,
the amount of equity securities issued (without prior shareholder approval) is more than 15% of the number of ordinary shares on issue at the start of that <FONT STYLE="white-space:nowrap">12-month</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Listing Rule 7.2 exception 9 provides that an issue of securities under an employee incentive scheme does not detract from the available 15% limit under
Listing Rule 7.1 if the issue of securities is made under an employee incentive scheme and that employee incentive scheme was approved by shareholders no more than three years before the date of issue of the securities. The ESOP is regarded as an
employee incentive scheme for the purposes of Listing Rule 7.2 and this Resolution 3 seeks shareholder approval for the ESOP to meet the <FONT STYLE="white-space:nowrap">3-year</FONT> approval requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends that any issue of options under the ESOP does not detract from the Company&#146;s Listing Rule 7.1 15% entitlement. Accordingly, it is
seeking shareholder approval in order for the Company to be able to issue options pursuant to the ESOP (<B>Options</B>) and have those Options qualify under exception 9 to Listing Rule 7.2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information required for Listing Rule 7.2 Exception 9(b) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Listing Rule 7.2 Exception 9(b) requires the information detailed in sections (a), (b) and (c)&nbsp;below to be provided to members for approval under this
resolution: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(a)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Options already issued </I></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has previously issued 13,060,000 Options pursuant to the ESOP since
its last approval in March 2015. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(b)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Voting Exclusion Statement </I></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The voting exclusion statement in respect of Resolution 5 is set out in Part
C, Section&nbsp;2 of this Document. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(c)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Employee Share Option Plan Summary </I></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key terms of the Novogen Employee Share Option Plan
(<B>ESOP</B>) are summarised in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>What kind of option is granted under the ESOP?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Each option is an option to subscribe for one fully paid ordinary share (<B>Share</B>) in the Company (<B>Option</B>). The Options are at all times subject to the provisions of the ASX Listing Rules.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Who can participate?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any employee (full or part time) or officer of:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Company;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;any company that is a related body corporate of the Company; or</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;any company in which
the Company has voting power of at least 20% of the voting shares,</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">who the board of
directors of the Company decides in its discretion is eligible to participate (<B>Participant</B>).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Who manages and administers the ESOP?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The board of directors of the Company, or a committee appointed by the board of directors of the Company (<B>Committee</B>).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>How many Shares can the Company issue?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time, the aggregate of the total number of Shares:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;which the Company would have to issue if all Options granted under the
ESOP which have not lapsed were exercised;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;which the Company would have to issue if all options which have been granted under employee
incentive schemes of the Company, which have not lapsed were exercised; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;issued under employee incentive schemes of the Company during the period of 5 years
preceding that time,</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">must not exceed 5&nbsp;per cent of the number of issued Shares at
that time (whether fully paid or partly paid).</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In working out the aggregate number of Shares the Company can issue, disregard any Share or option for a
Share issued:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;to
or by a person situated outside Australia at time of receipt of the offer;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;by way of or as a result of an offer or invitation pursuant to a disclosure document;
and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;by way of or
as a result of an offer which does not need disclosure to investors because of section 708 of the Corporations Act 2001 (Cth).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>How are Participants invited to participate in the ESOP?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee may from time to time give a Participant notice inviting the Participant to apply for Options. The invitation will specify,
among other things:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the number of Options for which the Participant is invited to apply;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the amount payable (if
any) by the Participant as consideration for the Options and the terms of its payment;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;the exercise price;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;the Vesting Period (as
defined below);</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;the Option Period (as defined below);</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the exercise
conditions (if any) determined by the Committee to be applicable in respect of each Option;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;the closing date for applying for each Option;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;how the Company will
during the Option Period make available to the Participant the current market price of Shares; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;how the Participant is to apply for the Option.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>What is the vesting period for each Option?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Either two years after the date of grant or another period as determined by the board or Committee (<B>Vesting Period</B>).</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>What is the option period for each Option?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The period starting on the date the Option is granted and ending (unless another period is specified in the invitation) on the fifth anniversary of that date (or some other date as determined by the Committee from time to time)
(<B>Option Period</B>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>When do the Options lapse?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Option lapses:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;on exercise of the Option;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;if the Option is not
exercised - at the end of the Option Period;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;if the Participant:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dies;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;ceases to be an
Employee during the Vesting Period; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;ceases to be an Employee after the Vesting Period and the Option is not exercised within 30 business
days after that happens;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;if the Committee becomes aware of circumstances which, in the reasonable opinion of the
Committee indicate that the Participant has acted fraudulently, dishonestly or in a manner which is in breach of his or her obligations and the Committee (in its absolute discretion) determines that the Option lapses; or</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;if the Company
commences to be wound up;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>How long will the ESOP last?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The ESOP will continue until the Board or Committee decides to terminate or discontinue it. The Board or Committee can also decide to suspend the ESOP for a fixed period or indefinitely.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>How can the ESOP be amended?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Board or Committee may at any time by resolution amend and modify the ESOP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Can the Options be transferred?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Option is personal to the Participant and is not transferable, transmissible, assignable or chargeable except:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;on the death of the
Participant after the Vesting Period and before the end of the Option Period, with the written approval of the Committee; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;otherwise with the Committee&#146;s prior written consent.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>What happens in the event of a share consolidation or <FONT STYLE="white-space:nowrap">sub-division?</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As required by ASX Listing Rule 6.16, the options terms allow the rights of an option holder to comply with the listing rules applying to a reorganisation of capital at the time of the
reorganisation.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>What happens in the event of new issues?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The options holder may not participate in new issues without first exercising the option.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where after the Vesting Period but during the Option Period of an Option, the Company
makes a pro rata offer or invitation to holders of Shares of securities of the Company or any other entity, the Company must give the Participant notice not less than 9 Business Days before the Record Date to determine entitlements to receive that
offer or invitation to enable the Participant to exercise the Option and receive that offer or invitation in respect of the Shares allotted on exercise of the Option.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where during the Option Period the Company makes a <FONT STYLE="white-space:nowrap">pro-rata</FONT> bonus issue to holders of Shares and an Option is not
exercised before the Record Date to determine entitlements to that bonus issue, the number of securities to be issued on exercise of the Option is the number of Shares before that bonus issue plus the number of securities which would have been
issued to the Holder if the Option had been exercised before that Record Date.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>What happens to pricing in the event of new issues?</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where after the Vesting Period and before the end of the Option Period the Company gives holders of Shares the right <FONT
STYLE="white-space:nowrap">(pro-rata</FONT> with existing shareholdings) to subscribe for additional securities (except a bonus issue) and the Option is not exercised, the Exercise Price of an Option after the issue of those securities is adjusted
in accordance with the following formula:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>O&#146; = O&nbsp;-&nbsp;E
[P&nbsp;-&nbsp;(S + D)]</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N + 1</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">O&#146;= the new Exercise Price of the Option or the Minimum Price, whichever is the greater.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">O = the old Exercise Price of the Option.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E = the number of
Shares into which an Option is exercisable.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">P = the average closing price (excluding special crossings, overnight sales and exchange traded option
exercises) on the Stock Exchange Automated Trading System provided for the trading of securities on ASX of Shares (weighted by reference to volume) during the 5 trading days before the ex rights date or ex entitlements date.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S = the subscription price for one security under the renounceable rights or entitlements issue,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D = the dividend due but not yet paid on existing Shares (except those to be issued under the renounceable rights issue or entitlements issue).</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">N = number of Shares with rights or entitlements required to be held to receive a right to one new security.</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Further Voting restrictions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as Resolution 5 could relate to the provision of an Employment Retirement Benefit, in accordance with the Corporations Act, a vote on Resolution 5 must
not be cast (in any capacity) by or on behalf of any person who may be entitled to receive a benefit in connection with that person&#146;s retirement from a managerial or executive office in the Company (or any related body corporate), or an
associate of that person. However, a person is entitled to cast a vote if: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">it is cast by a person as a proxy appointed in writing that specifies how the proxy is to vote on the resolution; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">it is not cast on behalf of that person or an associate of that person. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This means that any Participant who
holds a managerial or executive office (or has done so in the last 3 years) is not permitted to vote on Resolution 5 other than as a proxy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting
Exclusion Statement: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The voting exclusion statement in respect of Resolution 5 is set out in Part C, Section&nbsp;2 of this Document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(f)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Resolution 6 - Approval of Increased Placement Capacity. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Recommendation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company desires to maintain flexibility to respond promptly to maximise opportunities afforded by capital markets, and to do this the Company again seeks
approval from shareholders for increased placement capacity. The most likely use of this increased capacity would be to take advantage of an opportunity to raise additional funds to apply to the progression of our lead candidates, GDC 0084 and
Cantrixil, through clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval has been sought and granted in the 2016, 2015 and 2014 Annual General Meetings and has been granted in each
of those years, although not always utilised. Equity Securities issued under Listing Rule 7.1A in the twelve-month period since each of the respective Meetings are set out below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.90pt; font-size:8pt; font-family:Times New Roman"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;of&nbsp;Equity&nbsp;Securities&nbsp;issued&nbsp;in<BR><FONT STYLE="white-space:nowrap">subsequent&nbsp;12-month&nbsp;period</FONT></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGM 16&nbsp;November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Nil</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGM 12&nbsp;November 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Nil</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGM 12&nbsp;November 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">23,487,465</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Directors believe that Resolution 6 is in the best interests of the Company and unanimously recommend that Shareholders
vote in favour of this Resolution 6. The Chairman intends to exercise all undirected proxies in favour of Resolution 6. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background to the
Resolution </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rule 7.1A enables eligible entities, after obtaining shareholder approval at an annual general meeting, to issue equity
securities up to 10% of its issued share capital through placements over a <FONT STYLE="white-space:nowrap">12-month</FONT> period after the annual general meeting (<B>10% Placement Facility</B>). The 10% Placement Facility is in addition to the
Company&#146;s 15% placement capacity under Listing Rule 7.1. This Resolution 6 seeks approval to allow the Board the flexibility to issue additional Shares if it so decided. The Board may decide not to issue any Shares pursuant to ASX Listing Rule
7.1A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An eligible entity for the purposes of Listing Rule 7.1A is an entity that is not included in the S&amp;P/ASX 300 Index and has a market
capitalisation of $300&nbsp;million or less. The Company is an eligible entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is now seeking shareholder approval by way of a special
resolution to have the ability to issue equity securities under the 10% Placement Facility. The exact number of equity securities that may be issued under the 10% Placement Facility will be determined in accordance with the formula prescribed in
Listing Rule 7.1A.2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of Listing Rule 7.1A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any equity securities issued under the 10% Placement Facility (<B>Placement Securities</B>) must be in the same class as an existing quoted class of equity
securities of the Company. The Company, as at the date of the Notice, has on issue two classes of equity securities, being ordinary shares (<B>Shares</B>) and Listed options (<B>Options</B>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Resolution 6 is a special resolution and therefore requires approval of 75% of the votes cast by Shareholders present and eligible to vote (in person, by
proxy, by attorney or, in the case of a corporate Shareholder, by a corporate representative). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Listing Rule 7.1A.2 provides that eligible entities which have obtained Shareholder approval at an annual general
meeting may issue or agree to issue, during the <FONT STYLE="white-space:nowrap">12-month</FONT> period after the date of the annual general meeting, a number of Placement Securities calculated in accordance with the following formula: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional Capacity = (A x D) &#150; E </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">where:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>A</B> is the number of shares on issue 12 months before the date of issue or agreement to issue: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">plus the number of fully paid shares issued in the 12 months under an exception in Listing Rule 7.2; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">plus the number of partly paid shares that became fully paid in the 12 months; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">plus the number of fully paid shares issued in the 12 months with approval of holders of shares under Listing Rule 7.1 and 7.4; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">less the number of fully paid shares cancelled in the 12 months. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D</B> is 10% </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>E </B>is the number of equity securities issued or agreed to be issued under Listing Rule 7.1A.2 in the 12 months before the date of the
issue or agreement to issue that are not issued with the approval of Shareholders under Listing Rule 7.1 or 7.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issue price of Placement Securities
issued under Listing Rule 7.1A must be not less than 75% of the VWAP of equity securities in the same class calculated over the 15 trading days immediately before: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">the date on which the price at which the Placement Securities are to be issued is agreed; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">if the Placement Securities are not issued within 5 trading days of the date in paragraph (i)&nbsp;above, the date on which the Placement Securities are issued. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholder approval of the 10% Placement Facility under Listing Rule 7.1A is valid from the date of the annual general meeting at which the approval is
obtained and expires on the earlier to occur of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">the date that is 12 months after the date of the annual general meeting at which the approval is obtained; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">the date of the approval by shareholders of a transaction under Listing Rules 11.1.2 (a significant change to the nature or scale of activities) or 11.2 (disposal of main undertaking), or such longer period if allowed
by ASX </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(10% Placement Period). </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
effect of Resolution 6 will be to allow the Directors to issue the Placement Securities under Listing Rule 7.1A during the 10% Placement Period without using any of the Company&#146;s 15% placement capacity under Listing Rule 7.1. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Specific information required by Listing Rule 7.3A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to and in accordance with Listing Rule 7.3A, information is provided in relation to the approval of the 10% Placement Facility as follows: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(a)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Minimum issue price </I></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any Placement Securities are issued, the minimum price the Placement Securities
will be issued at is the price determined in accordance with the ASX Listing Rule 7.1A.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The actual number of Placement Securities that the Company will have capacity to issue under Listing Rule 7.1A
will be calculated at the date of issue of the Placement Securities in accordance with the formula prescribed in Listing Rule 7.1A.2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b) Effect on
existing <FONT STYLE="white-space:nowrap">(non-participating)</FONT> Shareholders </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Resolution 6 is approved by Shareholders and the Company issues
Placement Securities under the 10% Placement Facility, the existing Shareholders&#146; voting power in the Company will be diluted as shown in the below table. There is a risk that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">the market price for the Company&#146;s equity securities may be significantly lower on the date of the issue of the Placement Securities than on the date of the Annual General Meeting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">the Placement Securities may be issued at a price that is at a discount to the market price for the Company&#146;s equity securities on the issue date or the Placement Securities are issued as part of consideration for
the acquisition of a new asset, which may have an effect on the amount of funds raised by the issue of the Placement Securities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The below
table is included for illustrative purposes and shows the potential dilution of existing Shareholders on the basis of the current market price of the Shares as at 30&nbsp;September 2017 and the current number of Shares for variable &#147;A&#148;
(above) calculated in accordance with the formula in Listing Rule 7.1A(2) as at the date of this Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table also shows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">Two examples where variable &#145;A&#146; has increased by 50% and 100%. Variable &#145;A&#146; is based on the number of Shares the Company has on issue as at the date of this Notice. The number of Shares on issue may
increase as a result of issues of Shares that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements over the next 12 months under Listing rule 7.1 that
are approved at a future shareholders&#146; meeting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">Two examples where the issue price of the Shares has decreased by 50% and increased by 50% as against the current market price. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table has been prepared on the following assumptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">The Company issues the maximum number of Placement Securities available under the 10% Placement Facility. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 10% Placement Facility, based on that Shareholder&#146;s holding at the date of the Annual
General Meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">The table shows only the effect of issues of Placement Securities under Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">The issue of Placement Securities under the 10% Placement Facility consists only of Shares </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">The issue price is $0.04, being the closing price of the Shares on ASX on 30&nbsp;September 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Variable &#145;A&#146; in</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Listing Rule</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>7.1A.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$0.02</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>50% decrease in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Issue Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$0.04</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Issue Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$0.06</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>50% increase in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Issue Price</B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Current Variable</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>10%</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voting</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dilution</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>48,328,791</B>&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>48,328,791</B>&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>48,328,791</B>&nbsp;Shares</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>483,287,914</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Funds</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>raised</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$<B>724,932 </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$<B>1,449,864 </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$<B>2,889,727 </B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>50&nbsp;% increase in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>current Variable</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>10%</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voting</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dilution</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>72,493,187&nbsp;</B>Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>72,493,187&nbsp;</B>Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>72,493,187&nbsp;</B>Shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>724,931,871</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Funds</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>raised</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">$1,087,398</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">$<B>2,174,796 </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">$<B>4,349,591 </B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>100% increase in current Variable</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>10%</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voting</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dilution</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>96,657,583&nbsp;</B>Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>96,657,583&nbsp;</B>Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>96,657,583&nbsp;</B>Shares</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>966,575,828</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Funds</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>raised</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$<B>1,449,864 </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$<B>2,899,727 </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$<B>5,799,455 </B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table also assumes <FONT STYLE="white-space:nowrap">pre-consolidation</FONT> share prices. Where Resolution 4 in this
Notice of Meeting (<B>Consolidation</B>) is approved, any Placement Securities issued pursuant to ASX Listing Rule 7.1A will be issued on a post Consolidation basis, in which case the Share numbers and issue prices provided by way of example in the
table above would need to be proportionately adjusted to be reviewed on a post Consolidation basis. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(c)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Date by which Placement Securities may be issued</I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will only issue and allot the Placement
Shares during the 10% Placement Period, that is, at any time up to 15&nbsp;November 2018. An approval given under Resolution 6 for the issue of the Placement Securities will cease to be valid in the event that Shareholders approve a transaction
under Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or Listing Rule 11.2 (disposal of main undertaking). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(d)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Purposes for which Placement Securities may be issued</I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends that funds raised from the
issue of any the Placement Securities be applied for advancing the Company&#146;s key assets, GDC 0084 and Cantrixil, through clinical trials. The Company may also seek to issue Placement Securities as
<FONT STYLE="white-space:nowrap">non-cash</FONT> consideration or cash consideration for the acquisition of new <FONT STYLE="white-space:nowrap">in-licensed</FONT> assets, intellectual property assets or as cash for general working capital purposes.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total amount raised by the issue of Placement Securities will depend on the issue price of Shares at the time
of their issue. As at the date of this Notice, the Company has not formed an intention to offer any Placement Securities to any particular person or at any particular time, assuming that Resolution 6 is passed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The specific purposes for which any particular issue is made pursuant to the Additional Issue Approval will be disclosed by way of an ASX announcement at the
time of the issue. The Company will comply with the disclosure obligations under Listing Rules 7.1A (4)&nbsp;and 3.10.5A upon issue of any Placement Securities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(e)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Company&#146;s share allocation policy</I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s share allocation policy is dependent on the
prevailing market conditions at the time of any proposed issue pursuant to the 10% Placement Facility. The identity of the allottees of Placement Securities will be determined on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis having regard to the factors including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">the methods of raising funds that are available to the Company, including but not limited to, issues in which existing security holders can participate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">the effect of the issue of the Placement Securities on the control of the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">the financial situation and solvency of the Company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">advice from corporate, financial and broking advisers (if applicable). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The allottees under the 10% Placement
Facility have not been determined as at the date of this Notice but may include existing substantial Shareholders and/or new Shareholders who are not related parties or associates of a related party of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, if the Company is successful in acquiring new intellectual property assets or investments, it is possible that the allottees under the 10% Placement
Facility will be the vendors of the new intellectual property assets or investments. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(f)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Issues during the previous 12 months</I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total number of equity securities issued in the 12 months
preceding the date of this Meeting is set out in the below table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:81.50pt; font-size:8pt; font-family:Times New Roman"><B>Type of Equity Security</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;number&nbsp;on<BR><FONT STYLE="white-space:nowrap">issue&nbsp;at&nbsp;start&nbsp;of&nbsp;12-</FONT></B><br><B>month&nbsp;period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,153,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlisted options under ESOP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,240,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the details of all issues of equity securities by the Company during the 12 months preceding the date of
this meeting: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of<BR>equity<BR>securities<BR>issued</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issued to<BR>whom?</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purpose of issue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>approved&nbsp;by<BR>Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>issued<BR>including<BR>discount&nbsp;to<BR>market</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issued</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>for</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>cash?</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">31/10/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12,865,449 ordinary shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Kilinwata Investments Pty Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Purchase of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Glioblast Pty Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">n/a issued</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">under Rule 7.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9c per share, no discount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">31/10/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4,288,483 ordinary shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Miss&nbsp;Mi Ok Chong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Purchase of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Glioblast Pty Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">n/a issued</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">under Rule 7.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9c per share, no discount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1/11/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7,688,294 ordinary shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Dr Andrew Heaton</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Conversion of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Convertible Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19&nbsp;April 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1/11/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">497,297 ordinary shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Robert Birch</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Conversion of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Convertible Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19&nbsp;April 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1/11/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,630,956 ordinary shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Dr David Brown</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Conversion of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Convertible Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19&nbsp;April 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1/11/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">220,966 ordinary shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">David Archibald</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Conversion of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Convertible Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19&nbsp;April 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1/11/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">331,531 ordinary shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">John Thom</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Conversion of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Convertible Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19&nbsp;April 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1/11/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,630,956 ordinary shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phytose Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Conversion of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Convertible Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19&nbsp;April 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">23/11/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,000,000 unlisted options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Dr Gordon Hirsch</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Options to new</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">employee under</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ESOP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4&nbsp;March 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7/8/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">620,000 unlisted options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Gabrielle Heaton</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Options to new</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">employee under</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ESOP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4&nbsp;March 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7/8/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">620,000 unlisted options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Daniel Berg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Options to new</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">employee under</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ESOP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4&nbsp;March 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7/8/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,000,000 unlisted options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Kate Hill</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Options to new</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">employee under</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ESOP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4&nbsp;March 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Exclusion Statement: </I></B>The voting exclusion statement in respect of Resolution 6 is set out in Part C,
Section&nbsp;2 of this Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at the date of this Notice, the Company has not identified any particular person or class of persons who may
participate in an issue made pursuant to, or otherwise benefit from, the passing of Resolution 6.&nbsp;&nbsp;&nbsp;&nbsp;As such, no Existing Shareholders shall be excluded from voting on Resolution 6. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx443954_5"></A>PART E: GLOSSARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this Document, the following terms have the meanings prescribed below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Australian dollars.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>15% Rule</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Has the meaning given to that term in Section A of the Explanatory Statement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Annual Report</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Company&#146;s annual report for the <FONT STYLE="white-space:nowrap">12-month</FONT> period ended 30&nbsp;June 2017.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ASIC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Australian Securities and Investments Commission.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ASX</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ASX Limited ACN 008 624 691 or the securities exchange market operated by it, as the context requires.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Associate</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Has the meaning given to that term in the Note to Listing Rule 14.11.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Auditor</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Grant Thornton Audit Pty Limited ACN 130 913 594.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Board</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The board of Directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Chair</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The person chairing the Meeting.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Novogen Limited ACN 063 259 754.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Constitution</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The constitution of the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Corporations Act</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Corporations Act 2001</I> (Cth).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Current Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Directors as at the date of this Document.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Director</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A director of the Company from time to time</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Document</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">This document entitled &#147;Notice of General Meeting, Explanatory Statement and Proxy Form&#148; and any annexures or schedules to or of the foregoing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Equity Security</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Has the meaning given to that term in Listing Rule 19.12.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Existing Shareholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A Shareholder as at the date of this Document.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Explanatory Statement</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Part D of this Document, forming part of the Notice.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Group</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Company and is Related Bodies Corporate (as that term is defined in the Corporations Act).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Listing Rule</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The listing rules of the ASX as amended from time to time.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Meeting</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Annual General Meeting of the Company convened by the Notice.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Notice or Notice of Meeting</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The notice convening this Meeting of which the Explanatory Statement forms part.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="78%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">An option to acquire a Share.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Ordinary Resolution</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A resolution of Shareholders that is approved by Shareholders who are entitled to vote on that resolution and who hold no less than 50% (in number) of all voting Equity Securities of the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Proxy Form</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The proxy form attached to this Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Remuneration Report</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The remuneration report set out in the Annual Report.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Resolution</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A resolution set out in the Notice.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Securities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Collectively, any Shares or other securities issued by the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A fully paid ordinary share in the issued capital of the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Share Registry</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Computershare Investor Services Pty Limited, Level&nbsp;4, 60 Carrington Street, Sydney, New South Wales.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shareholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A registered holder of one or more Share(s).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Special Resolution</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A resolution of Shareholders that is approved by Shareholders who are entitled to vote on that resolution and who hold no less than 75% (in number) of all voting Equity Securities of the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Trading Day</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Has the meaning given to that term in Listing Rule 19.12.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>VWAP</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">In respect of a quoted class of Equity Securities, the volume weighted average price of that class of Equity Securities sold on the ASX during the prescribed number of trading days immediately preceding and including the date on
which such price is to be determined, but does not include any transactions defined in the ASX Operating Rules as &#147;special&#148; crossings prior to the commencement of normal trading, crossings during the after hours adjust phase nor any
overseas trades or trades pursuant to the exercise of options over ordinary shares in the capital of the Company.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g443954t1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g443954t1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MBDZ[DHW]U2<:R3:6[22;U26QT7@_]N/6OB'K2?#_ ,;:+HG@K0O&]I?>%?\
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M3PMX0TG!U+5[A7CC:5V"2&TL4EFAC,HBE=Y)4BABD<D*1C?R2!NQXS9_$/\
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M?>-YSE(WU#6=+M+_ $F\NW&%R;^\#@GHNG8Z"FEI*/\ *[H6UCW?]J_Q]+X
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M].965E)!4J001P0:(Z1ETV#JO([#]J;X-K\8_A;J.GZ?;K)XM\->;X@\(R
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M_P!!LM+L[32[R"ZA^SW*7-I;Q(DQEA 1V<%F &3P,*[^X>WD><_\,T_ ,?\
M-)_!@QQ_R"8^,?C3YI+KL*R738[&Q^%?PYTWPCJ/@*Q\&Z#:>#-7DGEU/PW%
M8QKI5[+<F!IY+BU.5=W:VMR3US"A'*BE=WWU0[6.UL+&TTRQL]-T^WBM+#3[
M6WL;&T@79#:VEI"EO;6\*#[L4<,:(H[!0*0;?(XZ\^&'P^O_ !?:^/KSPAH5
MQXTLFMWM?$LEC&=6A>U@>UMG6Z&&+QVTCQ*QR0A"YP  [M*U].P6_ [ND 4
M% 'PK^UK^RW>?%[4=#\:^#K_ $+1_$MG;_V/KPUI[VVL]7TU'WZ9.)].L+N0
M7]I(\\67A(DAF12Z_9T#>SE>9+!QE2JQE*F_>CRV;3ZJS:T>CWT=]-3\A\2/
M#RIQ/6PF9Y96H83'TH^QK^W=2$*U-.]*7-2IU'[2G>47>'O0<%S)4TG\:?\
M#"WQ:_Z&/X=?^#3Q+_\ ,G7K?VUA?^?=7_P&'_R9^6_\0;XD_P"@_+?_  ;B
MO_F,_1O]EGX%Q_!#P#+::A/I^H>+O$EZ=2\1:IIIG>S,<!D@TG3+*:[MX)I+
M.UM"SY>&(F>\N6V[2M>!F.,>,K\R3C3@K0B]_-M)M7;\]DC]U\/N$8<)9+["
MK*G6S'&3]KB:M/F<':\:5.$IQA)PIQN]8Q]^<W:UCZ:KSS[L* "@ H * "@
;H * "@ H * "@ H * "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g443954t2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g443954t2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( % !/0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /V&\4_$#Q%X;^,&@Z*\EE_PK^;PUI*Z^KVH^W:=KGBGQ#J>
MB>'-8%]Y@V::-1TZTTZ:)EVAM:BFR/*-&P;%/P]\:H[?PQX)N?$MAJ-_J.H^
M$O!WB+Q=J^F6^GV^E^'X?&&I'0=*O;NVGOXIWAN-9BN5,5E#<O##;22NH51N
M .BN?C3X;LK.6[O+#5X396GCFZU6U6.RENM,_P"$$\06WA>[MIHTO=LESJ.L
M7MI%8+&[+,)M[M$JL5 (KKXS:;96#M-X9\1CQ!;Z_JWAV\\*1MHCZI:WFA>&
MU\8:I.;S^V!ITUG'X;DM[M'BO':5KJ&!$\YBB  OQN\+MJ7AW3DL]2(UVU\#
MSSW)DTJ--'F^(K>5X4L[JUEU);N\FFGV).UA;W4=L)X7E<(Y* &IX1^*5AXK
MU:UTJ/0==T@:G9^)KS1K[4O[+:UU5/!_B&/PUKZPI8ZE<3VS0WUQ9R1_:881
M-#<ATY1E !S$7Q"U:/P;\5-?U2^DMO\ A$/'_B+0=/N=+TNRN;JWTC2]1TRW
MM8Q97MQ'!>7'EW,J-)+(F0^X?,@! #4_COI^ES:@K^"_%T]K83^/8HK^W_X1
MW[/>Q_#/49K+Q?<V\<VNQS)%;V\#W, EBC>Y ,42F4;: (D^+=ZGC#3M#LM,
MNM;T?5?&'B+2+[5KDZ7I0\/6.B>#M$\28L[=;KSM5M5M]0:Z>>94FV^="L9=
M(@X!=TWX[^&M3TZXO;72=8>Y>#P=>:#I:3Z#->^(+/Q]JDNC>%)K=H-9>#2Y
M;F_@E$UOJ<MG-:( \Z*#B@#;\$^.;R_\ ZUXP\31/:/H^M?$-+BT>&W@N;73
M_"_BG7].L[*9+>:2&2^BL--@A9XY'6612ZD[Q0!PNJ?&+Q!I6A:#<ZG#X8\/
MZ\UKXS'B6PU)=8O;2WUKPDVE[-$TV2SDCD1KZ'4HYTN9Q(JQE#L<L 0#9TSX
MLZO=:CJFEZCH5GIMU#XQ\/:1I"&ZEE%_X?U35-)T/6+AV4!?[8TG5[V:&:.,
MM$4N=/E'RW!  .IUKQ3XCL/&>F^&;=?#L,/B"+4(=#%S_:5QJ0DT_0Y]3FUR
M^6)H+;^RX]0CCTXV"2K=.9A<I+Y:ND8!0L/&OB:3P?=ZS<0:#<:E/XS7PGX?
MN+1-0M]'NX;CQ/:>$[;5[JWEN9[A8$OWO)C'%.?.BMX]CIYVY #G=.^+6L7O
MB*V\//;^&[>\LYHM-U6"XEUF!=5U.76_$^AI_8FI"UEM-+1Y?#336]OJ9,ET
M;IK:)Q+ 'G .K\+^+O%.NZ=XOMQ8^';OQ'X:U)-(A^P7E[;Z))J<FGV5W<6=
MS)=1R7*_V=-=M%+/&A2Y$(: 1LY2( Y2Q^*>N2:UH6G:E+X;L-.NY=2CFUN/
M2_$-W8:X++Q1;^'K631[B*X\C1(;N21XXIM2FFB>4Q-$\L4J%P#>\!?$+4_&
M4NK6&[PZNHQ^'-)\0V2:=+=7::(^MSZS:1:!XE@:=9/[7L;C21]I$;6I;S'0
M10E T@!S3_$[Q797$46J7'A2PL/[6\86A\0C0/%5[ITUGX1N?#>F74AMK&_E
M;35_M74==C>\NKG[,L6C>8=H9B #T/PQXRO/$7BWQ?HZV-O%H.A6^COHFJ(\
MK7&KR3W>NZ=K$SJ1Y2V<.IZ--;0/&6\PVT[D[2E 'H5 !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % '!>(?ASH/B:^U^^U5KUSXA\'1^"KV"*6)(
MH=/@O[_4K>^LR8#)!JL-W?O)'/O8(T$+*@9,D Y%/@9X;2Q\-:;_ &UXD:QT
M+P[X5\+ZE;M<Z:1XLTGP7J@UO0(]?<Z87$T6JF::22P:Q:9;J>%\Q.%4V^0;
M?(U+CX.>$KR\^(=W=/JDH^(]M:6VIV_VJ)(='^S1#S)_#^VVW6-S<WR0W\SR
M-.&N;>)\!4V$V#8XWQE\)-27P^/^$9NM6UWQ7<>)-:U[4?$-[K6D:+K$MUX@
M\)7/A&\F0#P[-I1L_P"S$TVS>T2QMREO;F:WD%W$AE-O(-O(W=(^"FCV=UX4
MUJYO[NWUO1-"\$:9JXTR/3/L6L77@>U$>F2K=W^ERZE86WFM*LL=E>68NH1%
M'<JX4@FWD&WD=5X?^&^C>&[SP_>V=WJ<TOARS\9V5FMS+;,DT?CCQ!9>(]5>
MY$5JA9XKVQBC@V% L3,'$C$,#8-CF;CX,VUQ_P )?9'QGXKC\.>-=5U36]6\
M,I%X9^P1:GJTMI/<7%G?-X>;4H0L]G$Z1M>N@RP(93@&P;&A?_![P[?P36\U
M_K*I/_PM'<8Y[,,O_"V+B>YU_:6LF'^C/<2"TR#L&/-\[&2;!L.C^$6@V]_9
M:E;ZEK4-S9^)KWQ)@2V$D-T-4\,:?X2U71[J*;3W#:9=:3IL.2FRXCE9GBG3
M@ V#8R=)^!?AK1=%N=$L=7UV&)6\+MHES&F@6UQX</@S4/[3\.RV*VFA10ZA
M>076T37>JPW]Q=1HL=Q)(HY-OD&WR.GM/AIHMOX.N/!%S>ZKJFDW^LZAK.K2
MZE+:R7FK/JWB:?Q3JME?206D41L;J[N9[>2.**,_9I6C5@3NHV#8QKCX.:&E
MS>2Z!JNK^%;;4(]2AO=/T>/27LWAUK3]+TW61!'J6F71M9[NWT732\R'<KVV
M]<%VR 7)OA)X;E.@/'<ZK:R>&O&*^,=-DM[F%7$H6!)=$N6>V;[1H<HM+)GA
M;]X9+&WD\X/$#1L&QN7_ (+74-:35IO$&N^1!>?VM9:,9+&73M/UM='FT.'4
M[)Y[%[J%8[2XFD%F+C[*;B1IVB+,P8 E;P5IB^$M-\'VMQ>V-IHT.BC2[^!K
M=M0M;SP_<VE]INHDSV[P3W0OK*&>42P/',QD#H5D(H YA?A'I"RPR?V[XB5)
M)+:[UF*.XL(#KFKV.I:MK-CK-S<0:>D]A?0:MK5Y<J-/EM(BT=LICV6ZJ0#5
MB^'RQZ1XHL'\4>(YM4\5VL-C?^)B^E1:U!;6EG_9]FMG]FTR.UBEBM6E'G-;
M-([SR2,V[9Y8!"_PZ%Q9Z7IE[XHUV?2K"*QM;C2((=%L-*U&PTJ_AU#2K-[*
MSTM$L%MI((83+8?999;=!#*[!4* &QX>\'1:!>:EJ+:QJFKZAJ%I::<MYJ:Z
M:)K73[":^N+2 &PT^V%Y<"XU&YDEN[L3W$QV>;(VP9 ,N?X<VA\.:5X7L=?\
M0Z7IMAIM[H]\+2>Q=]>L-45!JQU5;NPFC-_<R+++]MMXX)XGN[@PN@F84 7/
M#GPY\*>$=:O];\/:>VFS7^E6.D2VL5Q<-8PVUC?:EJ"M;VTLC+#++<:E(7V_
M+B%-JJ6D,AL&QW- !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'R
M;\6[3Q5KGQ3FT'PU9>)]3O5^$Z7FB_V+X]NO!=AX:\07/B;4[.U\3:A'#J=N
MFIB,QVX:/[+J#>7:LGD,'"L 9GBJ\\36D?Q,\17?B?7#XI^&WB'X4Z+H36&K
M7^GZ(5U#2_ DVO&7PU!<+8ZC#K&I:YK"2?;;>X<QM#%"T;6ZD '5_&6+6M0^
M('@W1M+T;Q1XECE\"^/]1_L/PUXZN? ;IJ%IJ7@VVL-9GU"'5K%+EK4WTT,<
M;F<JU^9!$P1A1L&QFVGQCU_2?"WA*XLYM.\56FD?#/P/XO\ %NMZI%?VNK>(
MTUW6_P#A%YX]'MXMJ6>II<6&H7,CW23K+(\$*QIYK2H;?(-OD>B>%?B-KNN_
M$[Q9\/;JST."/P8MS>7^HVT]P[ZK8:J]G+X7BTF!YR5O;*UDNH]:+^8D$YL%
MB"K?+Y8!P#Z1<W?C'QI8V/CGQDGAV*TDTGQ5KMQXJ-DFL>.]=\5:5J6A^"/"
M4EW(ECH-U8Z"KZ#)+I26TBKXCM(2SZA$\L)L&QP=_?ZV_P .[C5$\5^++3Q'
MX#UCQ=#?>'HO%S/=?#S2[;Q<T[:]KY6]-Y\28/#>C6@TI 7O;>^BO)T5'E'F
M(;?(-OD>K^%;B:Q^+T"0>)M;U70?%WA[QCJMCJ-[XB37]%\6:G::]H\SVFC:
M7:3O:^$H_"=C<R:6%6&W:\2YQ)YLUI+(QL&QY[!XP\:G6]-TQK/75T0_M1:W
MI7_"5'Q):-;7&G1:CX@2/PN=*6\^WC3D$:1+ \/V8"V5A\H6C8-CIYOCMXIB
MT36=<30O#\D=UX/\2>,/"-F9]1AFMX?#7C/3_"+Z9XEE8E7N+K^U+2X$UHD(
M@:.XB:*7RUDD -X_$SX@:=XCDTC6M.\&M;Z/XE^&WAG7AI<FMO/-=?$%DM_M
M&D7%V41+?3[BZLG_ -)@W3HLZ[86",X!S6J?$?QKK^B:K:31:5X9\0:;XS^%
M9L-,AEUNVNH;+7?B98Z7;2WM[$QM?$_A+4M/MUV:MH]SY-R);ZSD@AD@)< U
MKKXV>(=(L9I-4TC1I+M4^(_AFQ^Q?VA';:K\2/!>O6VDZ+I=H)Y6=--UNVN'
MF2+=)/"]C<QB20(&(!/\4];U_P *Z_8SIJ=U%/XX^'6L>"]/L[.YNX].@\?Q
MZMHXT.]TZ!I#Y-Y)!KVM,LH'G-'I408L(1M-@V/.M-\=>(?"UFBRZCJ?B";X
M+Z%>^#-5^W7VJW7]M>*/$WQ*MO GA+4O$4=JDMUK-Q#X<T=M49?+DG<:N6B^
M>=6HV^0;?([^^^,GC"R\/V&JRZ#I=DMMKGBO3/$6L:G8>(K73;*P\/W-O%I>
MM7.@JCZYX>T+4H[@"XU.ZMKR+2'1?M<<D4Z2  P8]<^(^O\ BW1=+U+Q)I#:
M(OQX\3:#]DLK#6=+N)M(\.^#-6U^QTZ>[TW7(3<V226D<@CD#"2YCB>X\ZW#
M6[ %CPS\9M;,7@K2].T!);4Z!\,KW6X&B\6:W=F'Q]K5]HYDM?$4OVBWL4TF
MULOMLDNMW3R7N9((BLD>]P#D=?\ B#XQC\!:]H&E7JQS:?;>.?$6J>(+_4-4
M76!8K\;=>\,:9I^@W=O,IMY[6SLI1NF:11&EI;)&JR%XP#W?XPF^MH_AS?6.
MLZSI9@^*_P /[.YM=,OWLK35;/5?$-E8W5GJ\<2A[ZS\B23%N9%B9GW2*^U0
MIL&QXSHGB"_U#Q-XGM?$WB/Q5X2C\6:S\7_#.E>*;7QE:C38(/"OBVRTNSMU
M\/ZE ;?PI?:?IJ1VNGZC;2J\TVH7IN%,L]HY .8NE\5_8;Z^NAJE]I?PPN_B
MKJOB3P'JWQ1\2Z1K6BZ79:=X(UW0]-B\1:%>37GC"2+27U"XMIYII;2W;Q!%
M:3S*8ADV#8]=^+FL>($USX3:WX5OM7@.FZ?XP\:2Z#:W-Q#'XIL-&T?1;BZ\
M/:G:1L4O)9M(OM1%NLJOY=Z+:1<%2:-@V.(_M35?&.@Z?J6DZWK'B;1)?&GQ
MBUF;PMH'C2[\,^*_$?A2W\326^C:QX7U*.]MFO(O#R7=ILTF6[M;:3[?;JSA
M[>**0V#8IWVI:UK-O-X$\/>.O$]ZWQ<\+_"_6O!OBBXOKG3]=CL8M&U*'Q9J
ML#6_DC2;N2T\*Z7<W26T<*"?7Y6**TQ+ 'KGP;\2:EX\OM>\9W5Y<MI\6@>!
M_#%O9?:9A80:Y9:'_;_C"=;0L(UO5U7Q##I\LI7>#HIB)'ED V#8\<\(?&A%
M\7>-=>M?$TNNKXP\-?$37]%\-7TFI'3O#]S\,;BXB\-VMK#*B0VD&N>%$DU&
M?[)(3,]G)(><-0!ZKJ/Q;\6I'?II/AZPO)[31OAEJTGV>#4-4N[.V\9V/B.^
MUV\BT"RN8[WQ$--BT.)TL-.87;0RW$V)!;%6 .=N?BE\1H[Z^U/1[GP/KMC?
M^'_@>=!TJ+^UDT8ZG\2_$^L:#/J,/B'"7,VGXMS-NET\/Y<-JBPQRQSFY .O
MN?B9XFLO'&E>#;ZST:>"[EM?#FL7^BV^O/'IWB:?P%J?C&Y(U6[CBL[4+]@B
M6WTO_2;I[6]BNY9X3B!P#@_"7Q&UG2?#>EK%Y=_KUWX$^ R6]YK%UXFUVZU;
M4?%.C:_-J#0Z'92RM?:G%::/=W6RU^PM='S)+V[5+<2(?H'Z'T!\-_%D_CGP
M1X>\575DNG7.JVLKW5FC.T<%S:WES8W C\T!TC::U=U23+H'",2RDD [B@ H
M * "@ H * "@ H YC46\(Z)K5MX@U:YT32=<U*SB\-V>HZC>VMC=W]JEV]]#
MI%JUU,GVDB[G>588PS;I#QS0!4U3P%X)U/7;;Q9JWAW2;G7-.%M+%JMS"HD0
MZ<SS6,]R"PBN9;)V>2WEN$D:W)+0LAYHV\@V\BKXB\"> OB(NDZIKVD:?XBC
MM;.?^R+^.[N/+.GZJMM+<+!<Z==1K=6%TMO:NREI(I!$AP1BC;R#;R#6O!GP
MZB@TC5==T3PY967@RVMTTJ\O4MM.T_0["QEMYK2%F9XK>/3[:XMK66*&?=#%
M+#'(BJZA@;>5@V\K%/2XOA7'+H6O:1>^$3+)JGB*'P_J]EK%A*;[5_$UVMUX
MDM;*\CO&&IWM[>PQ23P!IF+V\1V@PIL-O(-O(R++X8_!JZU+Q-9V.B>';W4;
MN2Z;Q3I<.IRWK0W.KWRZQ/<7^D?VA(FFWTVHQK>)<""&82H)8G5AF@#4G^&/
MPL9O#^E7/A7PV9=(2^GT&PFCB^T&$WEO?:FYA>3S-5MSJ+VMU<?:1<(;B2*:
M7,K*Q-O(-O(WM'\!^#O#VLZCXAT7PYIFFZUJAN#?:A;0!)W^V7 N[T19)6T6
MYO%6XG6!8A-*HEE#R#=1MY!MY$X\&>%E6)1H=@JP>)IO&42B,@)XIN)+B6;7
M%&[_ (_WDNKAB_3,K<4;>0;>1A1^ ?AHLOBE(M \/^;JX4>*XE\LL8YISK'E
MWL7FG^S[>:Y=KYHT$"2R.UPZLS%R;>0;>1-IMO\ #?Q=<:EJFBS^&/$D[:MH
M&IZK>Z1J-EJN-8\.^7-X>N+R2QN9%BNK,01/ 'VX\L'!H S%\!_"6TDO?"*Z
M+X6M[C7OLFJW'AT36\5Y>0:/J#:C83V^G?:!/'IUEJ?F7$26Z);PS-(Z*K,Q
M)MY!MY%=O W@GQ'9^"['P[<Z*/#WP]\:KXB73]'-KJ,3:[I=KJJ16L]Y%=.U
MG>Q:KJHO[AY/-GDDAVRX,S/1M\@V^1T]U#X%\;7MG!/)X=\2ZAX,URVUJU@B
MO+/4+OPYK]FES;6MZT-O,SV-]$D]RB^:JD;FXR.#;R#;R)&\">#F7Q2K>'-*
M9?&UQ#=^*PULK?V[=6UI;V-O<W^?]9/#:VELD;C:R&%74AQNHV\@V\C,E^%7
MP[FLM,TZ7PCH\EGH\][<6,3P,S++J<L<^J&YF+^;?I?3PPR7273S)<M#&TZR
M&-2IMY!MY&M!X(\)VVL2Z_;Z%8PZO/JHUR6]C1UD;6!I-SH3:F(P_EK>/I%Y
M<VKRJ@:2.4ARQ ( ,FX^'WPYL%TC4[OP]H5G#X0LK6/3+NY"P6NDV.DS/>V'
MFM-*L+06%RTES USO%M*S31&-R6)MY6#;RL5C\/_ (7>+--TVX30?#FO:3$^
MJ7.F75H\=[92?VOJS:UJCQ75K.R7<4^M@WC*SR(+A!(H#H"#;R#;R.VU31M+
MUF.SBU6Q@OH]/U/3]9LDG4L+;5-*N4N].OHP",3V]S&DB'LR@XH YJ?X:^ ;
MF^U_4;GPEH<]YXHM)K'7YIK&*3^T[6Y\@W4<\3@QJT[6MJ\SHJ/*]K \C,\*
M,IMY!MY%%_A%\-)+'3=-D\&:+)9Z3<7EU9QR6[.XGU%H6U(W4[2&744O#;6W
MVB.[>=)_LL(E5Q"FTV\@V\CI&3PMJ&H:#JYETB[U&V.KV/AN\2ZMY)0TL8CU
MJUTPQRD3.(M-(G2,.4%F^X+Y;8 .9F^#_P ,9]%L/#LG@K0QHNE7^IZGIMA'
M;-!%8WFMW,UWK#VSPR))#%?3W$S7$"N(I@VV1&50 ;>0;>1TQ\(^&#JN@ZW_
M &%IBZKX6T^]TGPY>QVL<4NBZ9J$5K!>V&G"(*MM:RPV5K&8T4*%A55 &03;
MR#;R(-,\.>$O"^FOX=TO3]+T33M;O]8G.EVY2T34M2UI[S5-9>*/S%>>[N"U
M[<2",E@JR,,*GRFWD&WD22^#O"\]AH&E3:%ITFG>%A"/#]D\ :WTI+?2;K08
MHK6,\+"-&O;NR,;;D:&X=&!!HV\@V\CD;GX9_"71=,DMKWP]X=TO3KR[T*#S
M;RX-GNO].:YL?#L5K?3W22P7L(U.ZM+402I)LO&MX\H^RC;R#;R+]YX4^&5O
M.NIWFG>&K*3PE8:'9O.\]O8P:%IVAWD>M>'(;R-9XX;2WLKQ$NK0W"@1EF:(
MA9&W&WD&WD.7P_\ #36?$-MXPBM_#6H^(5LX=9MM9MKRVGG:R2TO-%AUE#;W
M)CEA^PSWEC]MVL&BS"9"L85#;R#;R*R>#?A9J.G:990Z9X:N]/U6PT"#1%M;
MJ)UOM/\ !T$\GA\Z-<6]SOFBTVUN[DQ26CDI%<R;F*2-DV\@V\CH- '@SPY:
MOX3\.W&@Z9;>&+4R3Z#8WMHK:%9SO)=^9=60G,FGVS-))(&E5%PQ(.*-O*P;
M>5@N/'?@>SBT^:Z\9>%+6'5HWFTF6X\1:1!%J<4<H@DET^22\5;R-9R(RT)<
M!SM)SQ0!;T_Q9X5U74;G1]+\2^']2U>S\\7>E:?K.G7FHVOV:00W/VFQM[EY
MH/*F98WWHNQB%;!.* -7^T+ 7XTK[;:#4S:&_73?M,(OS8+,MNUZ+/?YOV07
M#+$9MFP.P7=N.* += !0 4 4(M5TN>X%G!J5A-=L;T+:Q7EO)<$Z9/%;:B!
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M*],.HR6>G-!#<S!;B2;R[;RHY<@1%$?Y0 9WP(U_2M#0^$(?%&E^(O#L6F^
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M L=3\OPA!9ZO?2ZI>6=[8"WL=!N;VTU*>6RN[>.YA2&33KKY&A#L(P54[@"
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M@MY8V+N%&7 &2<5C5K0HN"DI2<[\JC%R?NJ[T2>Q[&59)C,VABZN'J8;#T,
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M%)TKU(-SC[.H]5**D^ /B#XN^*]/631]=\6V?C.+XR7OAV]TO0-!TEOA_9^
MM*\:7&FZE)_PE.H:!=6UPT/@^%YWNTOY+U=65[(6JF)X8]>2A3>L8NG[)23E
M)\_.X)KW4TU[^R:Y>76^MSR_K.>8VDG0Q&)I8^&:SH3IT:-/ZE'!4\7*G/\
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M;3DN[5VK^EV:/ X1UL+B'0@Z^!A.%"=O>I0J1C&I&'92C""EW45V.CJ#J"@
EH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g443954t3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g443954t3.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M2^J>,/&VKI!_:VJ2O(6ECLE:%(K:"221HXDRS-++([FWR#;Y'T/0 4 % !0
M4 % !0 4 % !0!\U:F? G[.UG>Z!\,O!\&K_ !.^+_B_Q)XGTSPI:7 36O&W
MB_5[UM0U[Q1XGU>97DT_PKI"WL3WFI3@PV-G'!:VR//+;V\X!@> _ OP_P#V
M2_ ?CCXJ?%/QI%JGC/Q-.GB3XP?%WQ$V-1\1:JSM%I>A:3#@O::!I_VB/3-&
MT.S0!4V!8C-,Y)M\@V^1E_'+XVI*/&G@?PIKMUX=T_P+I&E7WQC\:Z?)%;^)
M- A\3Z?'J'A;X9_#RVN"&N_BUXNL[BWAL9E61-,34+:=5FOKFUA!^@?H6_V9
M/@E;^'['3?BWXV^'^C^"?BAK/AI/#VD>$[5;6\7X2_#J+4[_ %'1/ =GJB*9
M=0UZX%ZVJ>(=7GDDN;_5]2O/,D:*&,$V#8^O: "@ H * "@ H * "@ H * .
M#^(OQ$T'X9^'O[<UL7EW<7=[:Z/X=\/:1 ;WQ#XL\1ZBYBTKPYX>TY2&O=4N
MIA@#*QPQI+<7$D5O!++& >5? _X0>(O#6O>,_B_\4-8N-;^+GQ-:%+^R%_\
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MD1P?LM_#C7?#_P .;_6M4\-Z?\<+@:!?GX@:A:^(=/\ "VGP?#**6\DC O\
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M>,/&DMM%J&B?"+P_>J3!J6HV[MY>I>--0@$G]C:$Y^<J;^]"6,&+L ])\ >
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M42ZT/Q-\76TK5;75%\1ZW=$17_A_X=W$UE%!9Z5#]FNM7M7FN;R2.RNH;:4
MZ_X]?$;5/A-X#T31?AKHVBW_ ,2O&VM:5\-O@_X5O5EL?#[>(;VVF>*XU%=.
MMV^P>&=!T#3]1U2YPL,7DZ6EJLD<ES#D [S0['PS\(/AU+/J]UI'A_1O#6E:
MGXG\9:X\DEOI@O2D^N>,/$M[<W3-((Y[]]1OI))6+!7QP%"@V\@V\CR/P1HF
MJ?&KQEX5^.OB_3[C1/"?A2+4;OX&>#KD20:D]OXCTQ].N_B9XRA#A5U;5-$N
M/*TO1I4/]EVD[SS$W]XRV0!]14 % !0 4 % !0 4 % 'QI^U'J<GCCQ9\&OV
M8;:TO+BS^,>NZAX@^(KQ"S2V7X1?#D6>J^*M-G>^?;<)K.KWGAO1I[:*-YFL
MM5O9(RCQJP/T#]#WGQC\6_ G@"]LO#%S>RZOXQN[-9]%^'7A.V_M[QQJ5C&W
MD+=6GARSD\ZUTI"C*VHWIM+*/RF#W"D8(!RNG?#GQAXT\1MXH^+^K6TVB6%_
MJK>$_A)HC"7PCI]G<0)IUIJ7C6^>&*3QSKS62WDWV:YC&F63ZHZ06\\MM'>,
M;!L>]*JQJJ(JHB*%1% 5451A551@*H   '3% 'QO\/O'ND?$WXW?&'XL7/BK
M1+?X5_ *VO/@SHD][>Z7'I-MXO2/3/$_Q3\:7>J7<?EZ7!;VLGA[18;N&_6&
M6"UU 3QH8P6 .KTG4M9_:%\06>L:;<7&E?L^^'K[S[*01JMQ\=-5M3(BW#1S
M1,%^$=I+L>+OK\\99@-,A3^T@#Z;BBB@BCAAC2&&%$BBBB18XHHHU"1QQQH
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<JJB@!0H   H EH * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g443954tx03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g443954tx03.jpg
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M ?_$ -0  0 " @(# 0$            )"@<(! 4! P8+ @$!  $% 0$! 0
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M-7HX)5=Q+T2P?F>'' P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M61@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MNW*#[39S/B&P1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & 1V>1_P =&NO(QJNJT*V6A]KJTT2UDL]-V-#P
M;6P2L,B[;&8V.!-%O7\:V=Q5D9E1]X#*E,FLV14+ZD$#8_N';^7W!E8V+LG;
MNPE6,TJM=C5*K!_W(W1T2ZTZUT5W!F-7T[+PSNGYO+^JO9:=QVX3:?-;N<T8
MR:G;=>7"C4I)\:J%S_VN%(_7,NWZ':Y^.F8?]VEGZ9/Y-?".GOQ\:I_3&5_G
M+G\ ?^UPI'ZYEV_0[7/QTQ]VEGZ9/Y-?"'X^-4_IC*_SES^ ;2\,/N_.IN)_
M(FB\@9_>=BW0XUP=_+5:G3>OX>LQ3:WJMA:0UG=/&5AEEG2U=*NJLV0%("?%
M"FJ)NJ10'Z>C[$RNEZA#/W+\KSMU<8N*2YNQX-\.Q=^/88#U.]L3</4+9>;V
M=D])LZ7#.J,+MZ&8G=F[*=9VE&5N"2N42E*M>7FC3SF<OSA\KC5NHUWBA4)$
M"2][1:W#:2K5<HJ-*:Q>&&O5ER"2IA3-9)AH+I=)0A3"U:)B B54>O2_3#0?
M79B>O9A?%VFX6J]LVO.DOU4Z)KM;[CQ?]KWJ0\AIECIMI=RF9SB5_..+QC8C
M+XJTZ/#ULUSR32?)"-,)%8S-VGGP, 8 P"8WPU<K%-+[]/I.T2(HZ\WRNUC&
M .%NUI![/:)F3K+Y/O-V(EM#?NBE@* "JX,S$P]$\UUU'T%:EI/UG8C7.91-
MNG&5I^DO\OI+N7-WG4WLK=2'M/>OV2U"=-#UF2A&KPMYN*I:EX>M5;,J<9.U
M7");LSGT].1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M_)6>W4^S5IA,QKNPUU'758BUYR#0=I*2L4VDFB";F/=/6('326(8!34$IO4
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M5YLU?4;<6J_%PYN#9!+L;8%HVO?KCLRZOC2-KO5ADK+.NQZ=@O9-P986[<H
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MD(" I.V.[ZDV<)^H /V%4Q#$_10)YO*?Q+D>8?#Z\T"JM"O=E5!VRV;K!MW
M0TC;*J@]*K7R''M#W;/7I!]'H]QBI@Z<)'.(%((A1%T9)#KX+?(37:5%J\&]
M[3)*B^96.67TA+V8X1;0K^4D%G%DU++*O/9+$S:5A.NZC$U^T7"SAPUZ@L5N
MDK5-=J(+4>6R3P(@4!,80   1$1'H  'J(B(^@  8!4O\UO/!CR2L=.X)<8'
M:FR2C>8D^PI&FG&6:W/82;D8^GZQK3AB=1"<1B91T+J043%1O\>1N0I@,V6Z
M7(1IBR"P1P#XO(\/>*>K-(K&:.+1$Q:\_L&19]AD)+8%H<'F+.HDX(4GQ;2.
M=N 8-53 !CLV:/4 ^@*).KJ2?(^3K0(\D.$&^* R9?&V>,JBNP:21-N#EW^%
MNO3A:8]K'I]!.#R;;1Z\: E^T)'I@]>H@,Q=&"('P8\R("C\,.354V!)'!AQ
M;"<W)'H+N$P<'U_9H:1F7L1%-U#$,)FUPK[ST^@7$LF7T$P95-8^4@^9\">L
MK#NS>W*'GKL='XV;EYR9JL%(+(IBBM==B2@7C8SU@(@)VJT+%'CF1.WH4&\@
MHF'H @">"2!:;RV24_/-%HK8W$OFCKSGOJ-NJSA;I9:I9#3"#<QXVM;KHJ#4
MAXR:30(1,D9?:_$)+@"ANKU4L@0?H#K=BTURD%DGA?S+U/S8TY"[/UQ*-$)I
M-JS:;"H"[Q%2R:\M8H +Z%EV@"1=1@JN0YX]\! 0?MNBA! P*)IVVFG0DVZR
M 82Y"<B-2\7M86#;>Y;8QJU4@6RIDB*JI'F+%*>T<[&MU:*%0CF<L4JH3L0;
M(@(_2=02)$44+*5<$"I_P3HVP_*7Y-K)S!V% N8_5>L[G$[$E4E#&5C(Q:KI
M(M]*:I9//;*WD)!D6+:O9'M*4JB+1=0X$,Y3 UR7FQH06%O*5Q"><R^)%QH%
M8;IK;-I[UKLK5A%%"HE?6ZM-GJ2M=.L<2$(6UP#]Y'IB<Q4DW*Z*AQ J8Y1%
MT?@20?>%KR5UW0Z#OA5R>E#4&"9VB5+JRW6SOB6%(L3^27_";6-X4?>T6N-5
M;"95PR<N 32;/%G"#@Q"F2$M4XUQ1!;3071<HHN6RR3ANX2370704(JBNBJ0
M%$ED54Q,11)0A@,4Q1$! >H9;).BM_\ \IVC^;LW_)KG)7$%5/[M=_\ <+EK
M_-#4_P#+E[RY/@0CZK[S'_S/B+_>WG_U36V1;[0RQ?Q=_LS<=OS%:C_\@5_*
M'Q?E),ZY & 5%.=/[_WCC_/+B?\ RNOEV/HD%NO+1)#%YN>&W^\QQ6>[&J4/
M\PVMQY+)W>#3:-A5D;!15&Z8;"JI 1;JNG1ABVI))LB @ NF %#_ !@]:H.C
M!"?>>73GD_X29;7=ED_F.SN,VV](U:P+.%O<>S>NG,NZ8Z\LYC'4%1P*;4?E
M;@X%["J,BB(B94.M=*2KV$%AGPX_NU.+/\V;G_6G>LHEZ3))-,I!K'S"XVP7
M*_0%XT[+*-F4E*M22M,G7)#G)6[Q#@HXKLR/ME.H#<K@QF[GM*<QFCA4H%$1
M#/M[=UF[H.K6M1MU<(NDX_G0?I+^]>*1KWJCL+)]2=E9S:V9<89BY'GL7'^Z
MS$*NU/#&E:QG1-\DI)*I7/+X(^6G:'=L708&Z!W 6?O@@!NGKT$:" B'7-P_
M>GH'^CF_V;?\0X67L<=2Z8Y_1:_]S,?[<\_L(^67_J-H3_;U\_$+'WIZ!_HY
MO]FW_$)_!QU*^GZ+\IF/]N=Y6? _R.5L< G<MEZ;0J)IF-"T*U^7N;F>+7@>
M)#,!"HO*6R:'E3L 4*W]U5-,JHE$P] '+5_JIHZLS>6L9EYCE?+S*'+S4PK2
M;=*\:+@?KT_V-M]RS]F.JZAI2TQW8>N=N=]W/5<RY_5J5B,>?EJHU:5:-LX?
MF0W[%I6:@\*M8MOD.L="PU?=6"*9IF:,7MF-"(H5:)*B0Q47+&IUE8IRG%,H
MB[>J#U-V .5=.=)F[%W<N=?/G<W*2BWBU'F\Y^6<O[(KO+/M3[TR\=0R72;;
MT?4[?T6U;=R$5RQE=]6E9A3@XV;+33HO/N2XT(0<V<<BC & , WU\</*5?BO
MR7J\]*.%OR;[ .VU[LUB4%%D?DDR\23B["#0A516=5:9.FY^R0RIVAG"1/57
M,4WEH2UW19VK:7SVS6Y:?BEC&O=*-5W5H^PW/T'ZBSZ<[_R^<S$G]0YYK+9N
M.+7J[DDH7:*M79FU+!-N#G%>D;[\EO"KO67WAL&>X^#K8FI;'-*V*KQE@M+N
M"D:\,R /I6NE8(5Y^B6,B)559-D8JIA%G[8&^T4V8KHO4K2K>EV;6K^N^?PC
MRR<8J2E3!2KS+%JE<.-3<^__ &3=XYG=^>SNR?F"VUF+SNV87+TK<K7K/.G:
MY5;DN2$W)6VGZ'*GBF8*_8D<W/\ DZ<_2%(?BEGU/O,VQ_Y/R:^&8=^$CJYW
M:5_,R_@C]B1S<_Y.G/TA2'XI8^\S;'_D_)KX8_"1U<[M*_F9?P2</QB<$Y/A
MMKBUOMB_(7VY=AS &L3V =J2<;#56%.JC7*[&R3AHS57*JHLL^='*DF!UER)
MB!O8(8=8;WW3#<><MQR?.M-LQ\U25&Y2]*32;\(K'@F^TZ]]GOHYF.E>@YF]
MKOJ9[JSUWXV5N3G"%FW56K49-1;JW*Y-I*LI*./(F2?YA!T*1E>6?BWMOE]Q
M0_)%I9C!2%S_ "G4FU?#V&<0KT?\H@TIHD@?Y@X263]\HOD^TG3J;J/KZ95%
MI/$&4?&[H?8?&;AAIK26U6D4ROM);6]*>:PDJE-1B1YF^VBP,?AI-%-))R!H
MV51$W0H=IQ$OU8DZNJ!O)E((./,'XT+YS*-JK;''UO7T=WT-R>KS99J:3K*$
M]0EE'$S%.0F3I+$2EZ=8RF.U+V@91*06^T ID#*XRIQX Q'XIO'IS#XS\M-M
M[[Y+,:9[&R=;VJ.?3%>N,=/2,G=[+?*M:GSIU',6;4K=-]\O=+'4#H0%!  #
M[0=)DTU1$%B/+9)!OY#_  K:VY9V&8W)I>?CM-;SEC'>V0CI@LXUUL:4*7J6
M3L+*-+\QK=G<'*7WI5D1<%^WO7:K+"*V5J;6'8".2LZ8^\*<8FHT?7=@L-]J
M441)E#+EN^H]I0J3!HF5!JC!CM==.U1$<BD4"IMS)-@* =.SITRJL&1B?U8>
M+/GRY?)'IVZK\]UU19) [291F]A4&AU9\R6.'NM9BN:21D9FP)F*'7VG#=5(
M>G01#TR*P7 $MWCT\1.E^$#I#8T[*!M_?AV2S1.^246E&P%*;O4C)/F6O*Z=
M5X>,7=H*"BO).%EGRZ/4A!;I**(FIE)O#L))<\I!_)R%4*8ARE.0Y1(<AP Q
M3E, @8IBB @8I@'H(#Z"& 4Z=E^%OGK4]F\E(OCNUUZWTEM^3L-;8MW>Q&$6
M^EM4NKY$[ KM?DF+Q@HY8+QDC!,4U! PF,5N<O<*:ANMU2C3'B061?'MQ@4X
M@<2M4:4E$X_\,8R,=6'8SN-.FNV>W^TO%9BQ>V]3(F$@A%*."1[=<0 5&K-(
M>@!T +<G5U)-T\@&.-MZDUUO77=HU3M>JQMRH=PCSQL[ RB9A272[BJMW35P
MD9-U'R<>Y3(NU=('3<-ETRJ)G*<H"$IM8H%7_;'@]Y<\;]AO-I>/C><@Z;I_
M$&BHAU<U]9[7BF*R@&_!\]C;%;4ZZ1W:'0QWBD:"@!T.@<>IS5J:?I$'N2D_
MO):+<M?*PG#E(F#4LJLRXL+.>TI?;!0TVHJ8ZA^GK[I@$XCZB/7UQ\6,3CTG
MPN\[N6%XB+]Y N0CV*B6INY:(/<5-H[%28G<>\XA:^FF!M<T=LY*8P LV5?$
M1$0_S4_T YHKT068]!<?]3\8]80&H=,51I4J57R'.FV1,=S(2TFY @R-@L,J
MN)GDU/RJB8&<.EC&.;H4A>U,A"%H;;Q9)F;(!#5Y!?#;ICF9+R6TZ/,)Z6WN
M^2ZR]E8Q)).G; 622*F@I>JXBLS6"7["%3^:LE$W(D_QZ;KM(!:XR:P[ 1!5
MS@GYSN)!T:UH:_3D_38X5?EK&@;EK<M1B>X<3&%M1]LK0Q&!SCZB!8\I>HCT
M,.55@^)!D5QKG[QOLQNK7INS6&KQDBD9F\?*6_CW3R)-5B"BL*KVG]TV!#)"
M/44"&4'J/0!'%8#$D0\07C6W1P0?;CM.Y;9KZ6DMI1%+BH^OT5Y.2WR8M9=V
M!ZY<2DO+0\&@LJZ--%(5-!)0I?;$PJ#U  IE)/@2=7YHN!'(;F\3CR30\15)
M4NNC[-&U!9[4UK()$M*5+3B@9_$MU_C/<^2./<[>G9T+U_A8@TN(-$H+A_\
M> JQ!PU:K^^$8J!KT5'04)%M=Q5@K6-B(AFC'QL>V*:N&,"#-DW(F3J(CVE#
MJ(CE58$8G:_[K?WAG]8<WZ9*O^+>*P&)+1XSM9<_=;0>X$.>&P!OLM+S=17U
MHL-OC+;\LB6D;,)V1+W(V.CRL?B7RS4W:<#B?MZATZ91+E]Z2:=<H?';R8VK
MY8=.\NJA#T]?2]+L>A9*=D7]O:,; DUU_(*N+(9M7SMCN')T4C![)0.'O#]'
M3*HR2C3M(+ V6R3UK(HN456[A)-=NNFHBN@LF55%9%4HD5252.!B*)J$,(&*
M(" @/0< I_<B_!]R_BMT;U:\7$:.MQ]VA(I.HN)E;ZSKS@E?<34?=&U1E(=Q
M'B'LTVV,P"/4+U*#=%(2CW"<,NJ2ICQ(+&'CKT=?^-O##1FD=HM8ME?:%"V1
MC8FL-)I3,8DXD[S:9YJ#231322=%-'2J(F$"AVG$2_5EMXNI)NKD 8 P!@#
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MB'BK='>EQHXVTU29< SGH]01@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MVW"CP_$XT;SB-S[&V7 ;-/48U^I3(*,JSV'1C;8]*5FA8WRLA*R*;DT5&JN
M;)E(4Q'*I%@,!DB]<?W-U#^NM+EIN3L3L*Y)<\G).L%CRJB5*NE?##M-F=)?
M9>^P&\+6Z]>U"QJ#RMN3L6X6904;TO-5V3E.5>2#ER*F$VI5K%$WN:Q.NQ@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
)8 P!@# & ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g443954txpg3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g443954txpg3a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ C +& P$1  (1 0,1 ?_$ -,  0 !! ,! 0
M       % 08'" (#! D* 0$  04! 0$!            !0$" P0&!P@)"A
M 0,# @(%!@8.!P4( P$  0(#!  %!A$'(1(Q42(3"$%A<:%B%(&1L3(C%?#!
MT4)2LC-C<[,U%C8)<J(D-'2T=4-3M787\8*C1&0E53?A@Q@*$0 " 0," @8%
M" D"!00# 0   0(1 P0A!3$205%A<1,&@2(R% >1H;'!<K(S%=%"4F(C<S0U
M"/!TX<)3)!;Q@I(7HD.S&/_:  P# 0 "$0,1 #\ _<42=3Q/2?*>N@*:GK/Q
MF@&IZS\9H!J>L_&: :GK/QF@&IZS\9H!J>L_&: :GK/QF@&IZS\9H!J>L_&:
M :GK/QF@&IZS\9H!J>L_&: :GK/QF@&IZS\9H#RSB3"E:D_D5?** LBG9T@L
M7)-P+'CX<CH6+I<@"/=(KB>1E0(X2I()0UQTU2.9?F%;%K&N7=7ZL>MD1G;S
MB8;=N+5R_P!2^MF <AS&]Y(X??G^[B)5S,V^-JW%:(/9*DZE;[@_"62>K2I.
MU9A95(<3D,W<<K.D_&=+?1%<%];]++8YC]A5]VLIH#F/V%7W: <Q^PJ^[0#F
M/V%7W: <Q^PJ^[0#F/V%7W: <Q^PJ^[0#F/V%7W: E+5?+I99(EVV8[&>X!7
M*=6W4@Z\CS1!;=1KY"#YM*LN6XW(\LN!L8^5D8ESQ<>3C/\ UT<#.F.;I6ZX
M=W%OC:;9+.B!+02;>\KH!65$KB*4?PN9/'I%1US#G&KMZQ.KP?,%B]2WF?P[
MG[7ZK?U?.950M#B$N-K0XVL!2'&U!:%I/0I"TDI4DCRBM-IIT?$Z%.+7-%IQ
M?2N#.5"HH!0"@% * 4 H!0%UV0GW-?Z97R-_=H"6U/6?C- -3UGXS0#4]9^,
MT U/6?C- -3UGXS0#4]9^,T U/6?C- -3UGXS0#4]9^,T U/6?C- -3UGXS0
M#4]9^,T!Q4X$ J6OE2.DDGX@/*30$6]<5'LL:I!Z5J';U\I3Y!KY^- 1Q4HD
MDJ42222223J=>)H"FIZS\9H!J>L_&: :GK/QF@&IZS\9H!J>L_&:%5Q-.\I_
MB7("?_F+A_F7/N5.6OPH_91YCN#D]QO13I_$E]X@>'G^/_\ %9#4Y9_M?,8\
MS#;''<PYWUM+MMY7\RZ0$@..J^]$R/P1+2-.GLN=2A6WCYEW'X/FM]3_ $D!
MN_EK W5N<EX>:^$X\7]I<)+Y^TP\/#[E-OEES(9346R\X2Q-@\ZY$P*!(3W+
MNGN"R.'TNIU^:%5OO=;4XTM)^)U,Y%>1-QQ[O-G24<.NDH5<I+M7ZOI,LV3'
MK/CL7W2TPT1DJY2\\27),E:0=%R'UDK<5QZ."1Y *TKERY=ES3=3J</ Q<"U
MX6+!1CTOI?>^DFJL-L4 H!0"@% * 4!9V38+8LH27)3*HEQY=$7.'HB3J!HD
M/I_)RD#HT4-=.@BLUK(NV>&L.K_721.Y[-A;FG.]'EO]$XZ/T]:[/D-=<GP#
M(L9*WEM&XVT$E-QAH6I"$_\ JV=2Y%5YSJCVJEK.7:O:5I/J9P&Y[%G;=)SF
MO$QZ^W'7_P"2XKOX%B=XKR'4>0\>/KK:(0IWJ^OY?NT [U?7\OW: =ZOK^7[
MM 3V-XWD>7W)NT8U:9MXGN$:LPVE+2RE1T[V4^HI8B,)\JW%)3I6*]>M8\.>
M])1CVF]M^V;ANN0L3;K,[U]]$5HEUMO2*[6T;P;<>%.UVTQ[KN-,3?)R>5Q.
M.077$V:.L $(GRNP_<BD]*$AMK4??BN<R][G-.WBKEC^T^/HZCV?R]\,,?'Y
M<G?YJ[=6OA1?\/\ ]\N,^Y47:S;N'$BP(K$*%'8B1(K2&8T:,TAAAAE T0TT
MTV$H0A(Z !4#)N4G*3;D^+?%GJMO'M6;<;5F,86HJB44DDET)(NJSGZ!_P#3
M)_$-8+GM>@WL94B^\FFW7&5A;:U(4/*DZ:CJ(Z"D]56&R3L:[A>B9 *%<!WB
M2KD/G4G[TZ_!0$N%\PU2OF!Z"E6H/PB@*ZGK/QF@&IZS\9H"H)T/$]'6>L4!
M0])])^6@*4 H!0"@% * 4 H!0"@% * 4 H"U,LRFR8Y;92KE* D*85W4%GE=
MF/'@1RM!0[M)_"7RI\]9;=F[<?JKU>OH-+,W'$PHUO2]>FD5JW^@U0R?<B]7
MSO(T0FTVY1*>YCN*]Z>1J=!)DI*5Z$=*4<J?)QJ1LXL;?K2UD<?F[UE9=80K
M;LOH3U:[7]1CDDGI^SK)\I)K:(ANI2A04 H!0"@% * 4 H!0"@+KQ[,KWCCB
M1"D=[#U^DM\HJ<B+'E*4\P4PO3[Y!'GUK!=Q[=U:Z/K-_#W++P95LRK;Z8O5
M?\/09]QO<"R9#W<=:Q;;DH!/N<IQ(0ZK3_RLGLMO<>A)Y5Z>0U'7<:=K5:Q[
MCK\'><7-I"3Y+W4^GN9?-:]27% * 4 H!0"@% 759/[FY^F7^*U0$M0"@% *
M 4 H!0"@% * 4 H"-N1/*R/)S*)&O20!H?@"J B: 4 H!0"@% *%5Q-/<I_B
M7(/]8G_YEVIRS^%'[*/,<_\ N5Y]'/+[QU6ZQ3;AHL)[B.?]LZ" 1^;1P4LG
MR'@//2=V,>&HQ\6_?HZ<MOK?Z.)?EOLT*VA*FT!U_0A4AW13FOEY0.RV/1\=
M:\IREW$QCXEJSJE6?6^)TY&VAVQ75+B0H)AO.@$="VD]XA0ZB%"JVJJXFN*9
M3<8QEA7>95I;;^34U^J5.$% * 4 H!0"@% * 4 X$$$ @@@@@$$$:$$$$$&@
M,6Y3M79;YWDJU\EDN*M5?0MZV^0LZD]]%3IW*C^$WIYP:V[.;=M>K+UH?/\
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M;YCR*;42G7AJD@@Z>0\: N.@% 5'0?1]L4 /2?2?EH"E * 4 H!0"@% * 4
MH!0"@/!<KI;K/&5+NDQF''3KHIU8"G% 'L,MC5;RSIP"035T(2N.D%5F&_D6
M,:'/D24(]O3W+I,'Y+NO,E=Y$QUI4".>9)N+X29K@\BF&^TW&'43S+]%2-K#
M4?6N.K[#E,[S!<NIV\-<L.#DUKZ.HPO<WGI#,MY]UQ]YU*E.//+4XZXHD:E;
MBR5*/PUNI**I%41SDG*4G.;;D^+;J6,>D^D_+0H4H!0"@% * 4 H!0"@% *
M4 H"H)&GF.HZP>L'I% 9%QK<F\V,-QIA-VMR=$AF0X1)80-!I'DGF5H!T)7S
M#T5JW<6W<UCZLB9P=[R<.D+E;ME=#>J78S/=ARFRY&SSVV4"^E(+T)XI:ELZ
M_A,E1+B=?OD%2?/4=<L7+7MK0Z_$S\;-5;,M>IZ-%P?9\736+CJ;HH!0"@%
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M@Y$K4G2BFDZPN1_<N0<9P_=DC8NWL*C16VU#19YEK'4IS3A\"=!6R<X>R@%
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M&<4!)VD$RM=#H&U:^;70#XR* N6@% 5'0?1]L4 /2?2?EH"E * 4 H!0"@%
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M-N?;"5$\#6E>D&QV#;J93EGB&\3>UUV%K_=C9]>RPQ!46$IBYD;@;?N9-?\
MZWF%]:9Y%R; CZ(;[IKL]KIJE-*@SQ5 * 4 H#Q.?/5Z: X4 H#$US_:,_\
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M6GWIT9GB-$9C#5M.J_*XKBKSZ=0K2.F/5K0"@% * J.@^C[8H >D^D_+0%*
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M$^V$E*B69M]G:+MK>;'BSMV&U=4YSN4M3]6<X\\I<KMJDFUJX\R+O+?FS/\
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M!MOCF.;=7^UYLWC&-W^ZVXY;N9FLS'I-PA8OAN&XTU(EN2ICC7?/AIID+<6
M"T]9\$#%/BDW2C_R_M_<EWIAI=E8YXBO"S=,&M,522$WGQ/>'>UM1]GXW=)U
M[R[Y]BF1)A)3^4=5 X?-X52YEW ]UXVHN?@ZVE_E_P"Z%SM5YR.T^&:ZY6/$
MK*L-NEW>\PF/$9ATJ+NANS(MD%I^?<8V*;BST2;DI"%NMVYQQS3E0=%?:77^
MD&SF\7C8\/=IVKOTO;G<W!MZ\]S/&[G8=J-K=K,GL^<9MN1EN16Z1:\>LUJQ
MZQ29UQCPG9TM"ITN4TS&@Q$N./J0$$53E==> -3=F(T?^7=N;A=JW]N+-@VM
MW<\+OAWVX?WFD(>5@.&;Z[$V.Z8]>\%R^_(;7#QFW9-:;T)%GF2BU$?7'6WS
MA5&^;5=8-C\H\4V.[@;U779W:S</;/<3;Z=X/M]MR,KF87?;+EUPM67V.=9;
M%C<:5>;%<YK%KAS;/>9;GNSJ.=]20M)T00;: US\!5L\&4+:/PG7F'X@67=X
MCMMMFM&#2/%GE4]A6;S<9A1G\=&TLG<-ZQJ6F;(4TW9_J[NFE@(2R"D 72;K
M3H!/8]LC-W^V\_F!X=C-S38-S+#X\LZW$V<RU&@?Q'>+ <9VXOF#W3OD$.MQ
M9<YDVZ< H<]OFO(/ Z4?%>@$KX ]Y87B.W=\76Z<> Y8KY=(_AGM6;XM)2MJ
M9AVY&*[77+&MP\/G-+2E;3UARRURF4\P',T$+Z%56225%U@^ESC2VU<JTE)\
M@/E\XZQ5@.% * 4!XG/GJ]- <* 4!B:Y_M&?_C)'ZQ5;\/97<<U?_J9][^D\
M-7F,$@ E1"4I&JE*("4CIU43P  HM=!5)5? QQE>5PE1)%KMJ_>77P&I$E&A
MCMM:_2-MK_VKBM--1V0->-;5FP^93G[*.=W/=+3MRQK#K*6C:X)?68KK>.9%
M * 4 H!0"@% * 4 H!0"@% * 4!B?>;^$&?]<@?J)M;NW_CO[+^HYGS;_:X_
MSE]V1JY4R>:GU%\ W\#[@_\ -]N_X&FN1\Q_CV_L?\Q]!?!S^T9O^YA]Q&^%
M<Z>OB@% * 4!4=!]'VQ0 ])])^6@*4 H!0"@% * T'\7.5W]O)+-B+-QDQ\?
M58&;I)M\=Q;+4^9)G36.><&RGWE##,4!M"M4)U)T).M=#M%JWX,KK2<^>FJX
M42X'COQ(W#+6=;VR,W'#\%3<4Z*4G)K7K22T7!<>)IK4L>9"@% <'?R3OZ)W
M]6JJKB6S]A]S-8%=)^#Y!4NCD'Q?>7QMSDEYQG+K%(L\]^()=WML.=&0XOW2
M?%E3&8[S$R/KW;Z2VX="1JD\00:PY%N%VRXS2TBZ/I1*;-FY6%N%J6--QYKD
M4UT--I--<'])]3%)T44C7@2 /+H"0/)YJY:E#WB6DFNTI52@J@% * 4 H#I>
M8:D)Y74A0\G6#U@](- 6]*M#J-5Q]74_[O@'!Z/O5CT:4!#E*@>4@@CI!!!'
MFT/'A0%* 4 H!0"@% * 4!)Q;8\^ M8+39'21VE<1\Q'#XS0%QQXC$8:-I[7
ME622L_\ >Z1\% ;7[9_P7;/\1<?\Z[4/E_U#[D=_L?\ ;(=\OO,ORM<EBH)!
M!!T(\M 6L,%P,+[T8'@P="^\#HPW&0X' KG#G/\ 57-W@7VN;IUX]-9_>LG_
M *MVGVY?I(K\BV'FYO<<+FK6ON]FM>NOAGY0/YM'A*ONSGB3N6Y6)66]7C;_
M ']D77-XJ[;;[E=_J#.0\RK.+!,=C,R5M-RITI%RB<Y&K$M3:?R)T]T\B;_9
MW#:(X5^48Y>+ZCJTN:&KA)<%P5'3I1^7'^4OPKSO*7Q%N^8=KLWKNQ;Y*>3'
MEC*;M9%5[S:DXJ5*SDKMNO&-QK]1F,?Y;/A&O_B)\3&+)R>QWVT[<;7/0-Q\
MYG3K;<[2F>FRW*.]CF+PY,AB*KWS(+ZTV%EM7.W#9?6"" :WO.._VMIV:YX$
MHRR[R=N%&G3F7K2Z>$:T[6CG/\=_A3N'G_XC8SW&S>M>7MLE#+R)2C.'-X<T
M[5F+:3YKMQ1JUPMQF^-#]B,G"L'ER)$J3@V$29,IUV1)D2,/QMYY]^0M3CSS
M[KEL4XZZZXLJ4I1*E*)))-?/L<G)BDE=NT2HO7EI\Y^MD]CV.Y-W;F#A2NR=
M6WCV6VWJVV[=6V]6WJR;?A0I41RWRX,&9;GF1&>MTN'&E6]Z* E(BO07VG(K
MD8)2 &U(*  !IH*P:O5ZLDDE%*,4E%)))*B26B22T2ZDM%T'&; M]RAOVZYV
M^WW*VR6TLR;;<8,6?;I+*5(6EF1 EM/0WV4*;20A:"D%((&H%"IS$."()M8@
M0?JLQ1 5:_<XQM:H 1W?U>JW%HPU0>[T3W)1W?*-.73A0$)CF'8;AR);>'X=
MB.(HGJ"YR<4QFQXX)JPKF"I@LT"%[V0KC])S:'C2K?$$G<;/9KRB,W>;-9[R
MW"E-SX2+Q:X%U1"G,Z]S.AHGQY"8DUG7L/-A+B?(H4!)<R@==3J>8$Z]*5@A
M25?A)4"0=>D'0T!:EEP3!,;N4N\XW@N$XW>9_.)UWQ[$<=L=UF!W7O1*N-KM
ML68^'2=5!2R%'II5L%Q2XD.X0Y-NN,*'<;?,;+,RWW&+'GP)C*OG,RX4MMZ+
M):/E2M"A0$#8,*PC$VY3.*83AN+-3@I,YK&L5L-@;FI7J%(F(M-OAIE(4"04
MN<R=#T4U!YXFW^WL"5'G0=OL"A38KR)$6;"PK&(<R+(;/,W)BRXUJ;D1I#:^
M*5H4E23Q!% 7+'B0XADJAPX<-4V2J;-5$BL153IKB4)=FS5,-MF7->0VD+><
MYG%!(!5P% =$.TVBW/3I%MM%IMDBZ2/>[I(MML@P)%TF'769<WX<=EVXRR5'
MZ5XK7Q/'B: ]JT(<3RK2%)ZB/M](H",?@$=IE7,!KV%?.'1\TG0'T4!&E*@2
M""".D$<10%* \3GSU>F@.% * Q/<_P!HS_\ &2/UBJWX>PNXYJ__ %,WT5?T
MEEWG*;99^9LN"7,&H]TCJ!*5:<.^>XH9 /2.*O-6>W:G<?5$B<O=,?$]7VKW
M4OK9BB[Y-=+RI29#O<QM>S#CJ4ED ='>'@IY7'I/#S5O0LPAP]KK.7RMPR<O
M23Y;?4N'_$@*S&B* 4 H!0"@% * 4 H!0"@% * 4 H!0&)]YOX09_P!<@?J)
MM;NW_CO[+^HYGS;_ &N/\Y?=D:N5,GFI]1? /_ ^X/\ S?;O^!IKD?,?X]O[
M'_,?07P<_M&;_N8?<1OA7.GKXH!0"@% 5'0?1]L4 /2?2?EH"E * 4 H!0"@
M/G+XN_\ [)M'_)]N_P")7>NCVC^EE_,?T1/#_B1_?;?^VC]^9JO4H< * 4!P
M=_)._HG?U:JJN);/V'W,UD;9>DO(8C-.R'W5!+3##:W7G%$<$H:0"M1/F%2^
MB59:(Y*,)3FHQ3<I/2G3J; [<[-7-^\6.YY,\;6PU=;9):ML?E<N#I:FL.H$
ME?::B()3Q YG/14=EYUM0E"RFY4>O1P^<[79/*U^659OY[\.*N0?*M95YEQZ
M%])]3&XT>/S(89;;3J>(0.8\>E2SJI1/G-<HVWQX'OL+5NTN6W%)'6_%C24E
M#[+;@(TU*1S#^BH:*2:*4EP*7+-NXJ3BFBV)N//-@N0E=\@#7N5:!U/]$ZA+
M@^(^FLT;U?:(F_MTX)RL:P71T_\ $MU0*24J!2H=*5 A0](/$5GJGJN!'--.
MCXE*%!0"@% * \DF&Q)!*T +'$+3P7Z.I6GDUH"VY=M?C J [UO7YR 20/:3
MH2/3T4!'=% * 4 H  3T4![(T&1*/800@=+BN".GR$_.] H"X8MM9CE*E#O'
M!QYU '17LCB !Y">- 2= * VEVS_ (+MG^(N/^==J'R_ZA]R._V/^V6^^7WF
M7Y6N2PH!0'(+4D: Z G73R:CH.G137M'9T K4H:$\.G3H&O7H*=X[."[-#C0
M"@% * 4 H!0"@% * 4 H!0"@% =+K#3PT6D:^10X*'H- 13T)UO52?I$:^0=
MH#3RIU)/P4!"N?/7YE:'S'JH#A0'8VTMPZ)'PG@/CH#43.\KN;E^OEKCJ$./
M%N<V(M3"CW[Y9?<0I2GNR4(7^"GR=)-3V-8BK<9RU;2?<>7;QN>1+,NX]I\E
MN-R2=.+H^)C3I.IXD\23TDGI.OGK;22X'/\ :*J!0"@% * 4 H!0"@% * 4
MH!0"@% * 4!B?>;^$&?]<@?J)M;NW_CO[+^HYGS;_:X_SE]V1JY4R>:GU%\
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M/_-]N_X&FN1\Q_CV_L?\Q]!?!S^T9O\ N8_<1OA7.GKXH!0"@% 5'0?1]L4
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M6V=-%",SJ6XX/6-5^>M.Y>G<T>B.IP]LQ\1J:7-=7ZSZ.[J+LK$2 H!0"@%
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MEG[G\QY4_N3LUJ> X'+\! T)T3Q/17G?DRO_ )C9;X^+>?\ ^,S[ _R/<?\
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M4XXLZ:Z)0D%1]/15KDH\>!?"$[DE&";D^"6IDRS[;/OH#UZDJAZ@$1(I;6^
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M&U:+DJ2?*OL^S6M<RYS?+#2-?236%Y?L8\?%RWXMVG#]5/LZR$ "0$I 2E(
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MBU>I,UC-PJ.GX#\AH"">_*N_I%_C&@/*_(CQ6^]E/LQF]2.=]U#2#IIT*6H
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MR8X1'O"%3&1HD2VP!*0.MQ)(0^!_W5>FM>YCJ7L:/YB:Q=XN0]3)7-'KZ?\
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M$=!' T!-6^4MQ19<)4>4J0H].@(!23Y>F@):@% * J.@^C[8H >D^D_+0%*
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M)E!ONI#++CP<:[(<+:"K1Q'S5:A/3TU?";3H:.9B6;D)74DKB5:HQG6R<\N
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@7U?A4!/]CVO50#L>UZJ =CVO50%1R:'YW1YNL4!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g443954txpg3b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g443954txpg3b.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ .@+& P$1  (1 0,1 ?_$ ,H  0 !!0$! 0$
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M6R<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT
MUTO6R<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT!B55=-3AF#GN<_$C&1^
M  .!QP.)* C'W&M?D]8D8,^#'.;XP=+QH#&U\_72_*/_ .) -?/UTORC^- -
M?/UTORC^- -?/UTORC^- -?/UTORC^- ?6SS:0^&ESC]8_?[J!9GCK:"MK__
M )!?&MK*W)>+B&M;4U&0>N3 !K0_,%>4TO#C^%'S*\G-WU5;TL/$ERO6RU3T
MNT53@8G7(-.4/DJ9X6X;^,DK5ERIK/ 4Z%U4[JGASMKVLLW#LTI+_B^^/QD=
MGFI:NOAK1ERGUJEJ:5VD.$N"S"\G2\O+JPV,TU_35"^TWB6.M.2E_,FO>:?<
MNPS9BUTE9=*:[;5U+J6,U!H[CM%<9J,QLROC8V"6GFRYQIN?O*1'B=><E"2@
MDWFHI,JKGT1PJUI3N*=2XENK'=G4DXZ.AI[6R'HBZW1:F@EGI(LF+(*FH9CA
MFTCK2YY[I*V2^V\9:61*,8V\=RA]B&I-F9[1N/\ ,*[ZY4?.+&['4C=XM7XI
M;6/:-Q_F%=]<J/G$W8ZD/%J_%+:Q[1N/\PKOKE1\XF['4AXM7XI;6/:-Q_F%
M=]<J/G$W8ZD/%J_%+:Q[1N/\PKOKE1\XF['4AXM7XI;6/:-Q_F%=]<J/G$W8
MZD/%J_%+:Q[1N/\ ,*[ZY4?.)NQU(>+5^*6UCVC<?YA7?7*CYQ8W8ZD/%J?%
M+:R&N5OI;P#[1%14.(PUPK:V"H&3 85%/412@CNK9&<X=QX$.YM:%W\Q'>>O
M%I[4TS0;CV:P5&DZV[4;4VMYQ+6.NU57TX)\V>9D^'[0J5"]G'O0A+JP^FPH
M[GTU1JXNWKW%.7XG)=KQ[30+EV<]H=)BZW[1375@Q(:R\5]%4=S554VJ)[DB
ME0O;9]Z.Z^A,HKCTWQJEIH5O%7-.47L;P[3G]RI]O;/B;D=J*1@)&MDJ;BZ
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M%2"G3:<'DUD7%@]! $ 0&UV8849)W97X<.&KS>! 2J ( @" ( @" ( @" (
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MD2R\&\("4M/TD_%N_*$!LB ("IN9_HCW[4!2@" ( @" ( @" (#Z 2< "3O
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MA98!L9:3++)(=.NQ:T!C3_GJ@9\7.P\"J+OSY?3D.^X%^F0Z9?FD=*CH:2+
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M02 X%E933TSL=X:YC [O8J5&<9K&+3125:%>@]VO"<)?O)KVF&O1J" ( @"
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MFGW,M7QE?_'U*I[OSW].1'?<"_3*?7^:1O:CEN$ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $!3(]D4;I9GLAB;E=+*]L431ONDD+6-'=*+3H69B345O2T17*S0;
MSVJ]GU@<YM=M-033QXXTEL<^Z5)(')#:%LT;7>DYJE4[*YJ]V#PY]'M*:Z]0
M\%M&XU;B#FN2/VW_ *<5M9JE5VG4$S6SVVVU4S:A@GB=7.;2>1,-8S2A9KI
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M^G25EQZ?X1<Z945">N#W>Q:.PYO=.P.G=I/LFT$L60EM/=:5LS<=P>M4AC<
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M+S'H^%5\.OJ.ON_+7E9?>SZCFLO+=T>?]3T?Z/ I*R.?EWGEGR9=1;63 0!
M7:;IV=/RA]%^D;G1^=O+#R/4.^L^K/J.[;+_ $5OWCY/^\]%^R4"KWON]1UM
MAY?]?^/W&UK26(0$1M%]FR?8/(=]Y_L[-^5;*7>^]_#F1;[R'Y/^[W#Q+M;]
MJ3?=;EN^ZWT//N\*OZ/=^_\ Q'RCB/S#^7S?D]TU9;RO" ( @ SK#R,K,[UV
M=?=MO1_3ZOH^5RF]+YWYOFX*JO?.Y?=U':\!_3E^.7MY?=S&]#..[NYN^H9<
M&U6CDC[+_1^D[GC7B63SS+.TR_I]69LIS[O?SK46!\0! $!6S/WO[P@+J (
<@).V=.[XIV;TV<K^Y 3J ( @*FYG^B/?M0'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
